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1. Introduction 
 
1.1 The Epigenetic Regulation of Genes 
 
The term “epigenetics” was coined over 60 years ago by Conrad Hal Waddington 
when he combined the words “epigenesis” and “genetics”. He realized that “the 
fertilized egg contains some preformed elements – namely, genes and a certain 
number of different regions of the cytoplasm – and (...) that during development 
these interact in epigenetic processes to produce the final adult characters and 
features that are not individually represented in the egg” (Waddington, 1957; 
Waddington, 1966). By representing a developmental pathway as a valley in a 
landscape, Waddington provided a simple mechanical analogy for the rather complex 
epigenetic mechanisms that occur in organisms during development (Fig.1). An 
important part of Waddington’s definition is the incorporation of cytoplasmic elements 
in addition to nuclear elements, which allows for the influence of extrinsic factors, 
such as nutrition, on gene regulation. This idea has often been underrated in more 
recent definitions where epigenetics has been described, for example, as “all 
meiotically and mitotically heritable changes in gene expression that are not coded in 
the DNA sequence itself” (Egger et al., 2004). 
 
Figure 1. The epigenetic 
landscape 
 
A number of possible pathways of 
development lie ahead of the cells 
of a developing embryo, and at any 
particular point in an embryo’s 
development these potential 
pathways can be switched.  The 
developmental pathways that could 
be taken by each embryo cell are 
metaphorically represented by the 
pathway taken by the ball as it rolls 
down the valleys. The pathways 
can be influenced either by genetic 
factors, or by developmental 
plasticity (the ability to respond to environmental factors). Up to a certain threshold, any 
genetic variation or environmental noise will be “buffered” and will not affect the canalization, 
but above this threshold, the cell (ball) would flip over into an adjacent pathway. (Figure 
adapted from Waddington, 1957 and Slack 2002; © (1957) Geo Allen & Unwin) 
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The transcription of genes is regulated in cis by recognition sequences for 
transcription factors (promoter, silencer, insulator and enhancer elements) and in 
trans by transcription factors that bind to the cis-regulative elements (Alberts et al., 
2002). In addition to the direct mechanisms which control gene expression, like the 
binding of activators or repressors to promoter or enhancer sequences, there are 
epigenetic modifications that control transcription by influencing the chromatin 
structure without changing the underlying base sequence. In this way they may 
control the accessibility of binding sites to transcription factors. Epigenetic 
modifications are cell-heritable, and can thereby lock in gene expression states 
throughout development and reproduction. Research has focused on DNA-
methylation and histone modifications (Fig. 2). They are often referred to as the two 
main mechanisms of modern molecular epigenetics that deal with the variation and 
inheritance of states of gene expression (Horsthemke, 2005a).  
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The two main components   
of the epigenetic code 
 
 
 
 
DNA methylation 
 
Methyl marks added to certain     
DNA bases control gene activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histone modification 
 
A combination of different    
molecules can attach to the ‘tails’     
of proteins called histones. These 
alter the activity of the DNA   
wrapped around them. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The two main 
components of the 
epigenetic code 
 
The figure shows the sites 
of DNA-methylation and 
histone modifications in 
the chromosome. Me: 
methylated cytosine base. 
(Figure adapted from Qiu, 
2006) 
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DNA-methylation is involved in the epigenetic regulation of gene expression, as 
certain gene regions allow the binding of transcription factors only if they contain the 
correct specific methylation pattern (Vanyusin, 2004). Histone modifications are the 
second important factor for epigenetic regulation of gene expression, as they can 
directly influence chromatin structure, providing a steric mechanism of control for 
transcription factor binding. Furthermore, the two hallmark mechanisms of 
epigenetics are closely connected and even interact in some cases (Fuks, 2005; 
Estève et al., 2006). 
 
 
1.2 DNA Methylation 
 
Pioneer studies in DNA methylation date back over 50 years, when it was first 
discovered that methylated bases can occur in DNA along with the four classical 
bases (adenine, guanine, cytosine, and thymine). 5-Methylcytosine (5-mC) was first 
found in various types of DNA by Hotchkiss (1948) and Wyatt (1950), although its 
synthesis and function remained unclear for some time. In 1963, the DNA-
methyltransferases (DNMTs) were observed for the first time (Gold and Hurwitz, 
1964). These are specific enzymes that transfer methyl groups from the donor 
molecule S-adenosyl-L-methionine (SAM) selectively onto cytosine residues in 
eukaryotic DNA chains. It became clear that methylated bases are not incorporated 
into eukaryotic DNA in a ready-made form, but originate from enzymatic methylation 
of cytosine in DNA chains that are forming or already formed. 
In eukaryotic DNA, methylated cytosines are formed mainly in CpG sequences, the 
regions of DNA where a cytosine nucleotide is followed by a guanine nucleotide in 
the linear sequence of bases (Vanyushin, 2004). In mammals about 70 % of CpG 
cytosines are methylated (Robertson and Jones, 2000). However, the methylated 
fraction of the human genome is rather small (about 4 % of the cytosines are 
methylated) and the methylated cytosines are distributed in complex patterns over 
the genome (Lyko, 2005). Regions of DNA of greater than 500 bp with a GC content 
equal to or greater than 55% and a ratio of observed CpG/expected CpG of 0.65 or 
more are known as CpG islands (Takai and Jones, 2002). About half of all known 
genes in mammalian genomes have CpG islands associated with the start of the 
                                                                                                                     Introduction 
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gene (Jabbari and Bernardi, 2004). The presence of CpG islands is therefore used to 
help in the prediction and annotation of genes (Bird, 1987; Gardiner-Garden and 
Frommer, 1987). Although the aforementioned context in which methylated cytosines 
occur has been widely accepted over the past years, a study published in 2009 that 
compared the methylome of human embryonic fibroblasts to that of fetal lung 
fibroblasts has now confirmed the finding of two previous studies that the 5-mC does 
not only occur in a CpG context in mammalian cells (Woodcock et al., 1987; 
Ramsahoye et al., 2000; Lister et al., 2009). This study showed that nearly one 
quarter of all 5-mC residues identified in embryonic stem cells were not in a CpG 
context, suggesting that embryonic stem cells may use different methylation 
mechanisms than somatic cells to affect gene regulation (Lister et al., 2009). 
Further studies found that methylation of cytosine residues plays a vital role in 
stabilizing the double helix, inactivation of the X-chromosome, differential inactivation 
of genes during embryogenesis, and genetic imprinting (Vanyushin et al., 1970; 
Riggs, 1975; Li, 1992; Bell and Felsenfeld, 2000). In many cases, cytosine 
methylation prohibits the binding of specific nuclear proteins involved in transcription, 
replication, and DNA repair (Bird and Wolffe, 1999). Moreover, many types of cancer 
use methylation mechanisms to gain control over the regulation of certain genes 
(Baylin et al., 1986; Greger et al., 1989; Herman and Baylin, 2003; Feinberg and 
Tycko, 2004).  
 
 
1.2.1 Gene Regulation by DNA Methylation 
 
First observations that 5-mC plays a role in the regulation of various eukaryotic 
genes were made in 1977 by the inhibition of DNMTs (Constantinides et al., 1977). 
Later studies showed that the methylation of CpG dinucleotides in promoter regions 
can control gene expression (Sutter and Doerfler, 1980; Vardimon et al., 1980; 
Langner et al., 1984; Arney, 2003), mostly by binding co-repressors called methyl-
CpG-binding proteins (MeCPs). These co-repressors can in turn recruit histone 
modifying enzymes, such as the histone deacetylases (HDACs), to the promoter 
region, which then sterically modify the chromatin structure to prevent gene 
expression (Bird and Wolffe, 1999; Jaenisch and Bird, 2003).  
                                                                                                                     Introduction 
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The methylation of DNA has specifically been shown to influence the epigenetic 
regulation of imprinted genes (Delaval and Feil, 2004), such as Insulin-like growth 
factor 2 (Igf2), which are expressed either from the paternal or from the maternal 
allele. This differential expression is regulated, among others, by DNA-methylation. 
As one allele is methylated, and the other is unmethylated, only one of the alleles is 
genetically expressed. In most cases, the unmethylated allele is expressed while the 
methylated allele is silenced.  
To date there are more than fifty known human imprinted genes 
(http://www.har.mrc.ac.uk/research/genomic_imprinting/, 
http://www.geneimprint.com/site/genes-by-species). Although there are no known 
common functional domains or protein sequences among imprinted genes, they are 
often clustered in certain chromosomal regions (Reik and Maher, 1997; Reik and 
Walter, 2001), indicating that the establishment and maintenance of imprinted genes 
may be regulated coordinately in these regions, referred to as imprinting centers 
(ICs).  
In contrast to the mechanisms of most known imprinted genes, where 
hypermethylation of promoter regions leads to gene silencing, the expression of Igf2 
is increased by the hypermethylation of certain CpG islands in the Igf2/H19 complex, 
whereas their hypomethylation leads to gene silencing. Various regions of the 
Igf2/H19 complex contain CpG islands which are regulated by the change of their 
methylation status (Arney, 2003). One of these regions, known as differentially 
methylated region 2 (DMR2), lies 3’ of the promoter region of Igf2. Methylation of 
DMR2 prevents binding of the repressor GC-binding factor 2 (GCF2), resulting in 
expression of Igf2 (Bell and Felsenfeld, 2000). Another part of the Igf2/H19 complex 
that is influenced by methylation is the H19 differentially methylated domain (DMD), 
which lies 5’ of the H19 gene region. Methylation of the DMD prevents binding of an 
insulator protein, the zinc-finger protein CCCTC-binding factor (CTCF), thus allowing 
interaction of the Igf2 promoter with enhancers downstream of H19, so that Igf2 is 
upregulated (Arney, 2003).   
 
 
 
 
                                                                                                                     Introduction 
__________________________________________________________________________________ 
6 
 
 
1.2.2 DNA Methyltransferases 
 
There are two basic categories of DNMTs, “de novo” and “maintenance” DNA-
methyltransferases. The maintenance methyltransferase Dnmt1 prefers to methylate 
newly synthesized CpGs whose partners on the parental strand are already 
methylated (Bestor, 1992; Pradhan et al., 1999). As 5-mC is not available as a free 
base for incorporation during semiconservative replication, the newly synthesized 
DNA strand per se does not contain any methylation marks, resulting in hemi-
methylated DNA. The CpGs of the daughter strand are modified according to the 
original helix, preserving the methylation pattern during semiconservative replication 
(Holliday and Pugh, 1975; Riggs, 1975; Bird, 2002). Since 1995, various studies 
have also attributed de novo activity to Dnmt1 (Christman et al., 1995; Tollefsbol and 
Hutchison, 1995; Yoder et al., 1997), which until then had only been proven to 
function as a maintenance methyltransferase. One study even attributes a higher 
specific activity of Dnmt1 on unmethylated substrates than that of Dnmt3a and 
Dnmt3b (Okano et al., 1998). Interestingly, the preferential recognition sequence for 
Dnmt1s de novo methylation is CCGG, which is disfavoured by Dnmt3a and Dnmt3b 
(Goyal et al., 2006). 
The Dnmt1 gene is located on chromosome 9 in the mouse and has three mRNA 
isoforms, known as Dnmt1o, Dnmt1p and Dnmt1s, that differ in alternative first exons 
(Fig. 3). Dnmt1o and Dnmt1p are sex-specific isoforms that are only expressed in the 
oocyte up to the 8-cell stage and in the pachytene spermatocyte, whereas Dnmt1s is 
the somatic form that is expressed in the oocyte from the 2-cell stage to the adult cell 
stage (Mertineit et al., 1998; Cirio et al., 2008a).  
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Figure 3. Sex-specific exons 
and mRNAs from the Dnmt1 
gene 
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(a) 5' region of Dnmt1 on proximal 
mouse chromosome 9: exon 1o is 
oocyte-specific; exon 1s is 
specific to somatic cells of both 
sexes; and exon 1p is restricted to 
pachytene spermatocytes. The 
ATG codon in exon 1s is used for 
initiation of translation in somatic 
cells; a truncated form arises from 
use of the ATG codon in exon 4 in 
oocytes.            
(b) mRNA products of sex-specific 
exons. Effect of the alternative 
promoter use and splicing on 
organization of mature Dnmt1 
mRNAs are indicated. Heavy 
         horizontal bars indicate open 
         reading frames; short vertical bars 
         indicate ATG initiation codons. 
         (Figure from Bestor, 2000) 
 
Dnmt1o expression is driven by a promoter upstream of the Dnmt1s promoter, which 
introduces an untranslated exon (exon 1o) that shifts translation initiation to a start 
codon in exon 4 of Dnmt1. This results in a truncated form of Dnmt1s that lacks 118 
N-terminal amino acids. Interestingly, Dnmt1o shows low levels of mRNA expression, 
but high levels of enzymatically active protein in the ooctye, and furthermore has the 
ability to travel from the cytoplasm to the nucleus and back (Carlson et al., 1992; 
Mertineit et al., 1998).   
Dnmt1p has the same open reading frame as Dnmt1o, but is expressed from a 
promoter which lies downstream of the Dnmt1s promoter. In contrast to Dnmt1o, 
Dnmt1p shows high mRNA levels in the pachytene sperm, but so far no 
corresponding protein has been detected. This may be caused by interference of 
multiple open reading frames contained in Exon 1p, which may interfere with Dnmt1p 
expression (Trasler et al., 1992; Mertineit et al., 1998).   
Dnmt1s is the ubiquitously expressed somatic form, and is the only isoform 
expressed later than the 8-cell stage of the oocyte in human and murine adult 
somatic cells (Yoder et al., 1996). Dnmt1s is a large enzyme of 1620 aa that can be 
subdivided into an N- and a C-terminal domain (Jeltsch, 2006). It targets replication 
                                                                                                                     Introduction 
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foci using recognition sequences at the N-terminal end, which contains several 
individual domains for activity regulation and intracellular targeting (Gruenbaum et 
al., 1983; Chuang et al., 1997; Leonhardt et al., 1992; Jeltsch, 2006). The C-terminal 
end contains the catalytic center and shares sequence motif homology with 
prokaryotic cytosine-5 methyltransferases (Jeltsch, 2002). In contrast, there is only 
little homology between Dnmt1 and Dnmt3a/3b (Okano and Li, 2002).   
Dnmt2 is a well-conserved gene with orthologs in plants, yeast, Drosophila, humans, 
and mice. Although the motifs essential for methylation activity are present, the 
catalytic activity of Dnmt2 in mammals is still a controversial issue (Liu et al., 2003). 
The de novo DNMTs Dnmt3a and Dnmt3b introduce methylation marks into DNA 
helices that are not methylated on either strand (Okano et al., 1999; Goll and Bestor, 
2005). De novo DNMT activity is of special importance during the early stages of 
embryogenesis, after DNA methylation marks on the paternal allele have been 
erased actively (Mayer et al., 2000; Oswald et al., 2000) and some regions of the 
maternal allele are subjected to passive demethylation (Rougier et al., 1998). At the 
blastula stage the genome is remethylated, and this is one of the main functions 
performed by the de novo methyltransferases. Dnmt3a and Dnmt3b have a 13-fold 
higher affinity for the flanking base-pairs RCGY than for YCGR (R = A or G and      
Y= C or T), and also prefer AT-rich flanks over GC-rich ones (Handa and Jeltsch, 
2005). Dnmt3b has one enzymatically active isoform, Dnmt3b1, and two 
enzymatically inactive truncated isoforms that are produced by alternative splicing, 
namely Dnmt3b3 and Dnmt3b6 (Chen et al., 2003). The establishment and 
maintenance of DNA methylation patterns in mammals has been shown to be 
coordinated cooperatively by the Dnmt1 and Dnmt3 families (Lyko et al., 1999; 
Okano et al., 1999; Kim et al., 2002; Chen and Li, 2006).  
 
 
1.3 Histone Modifications 
 
In the eukaryotic cell nucleus, DNA is not present in a free form, but is complexed to 
chromatin by its association with core histones and other non-histone chromosomal 
proteins. Partially unfolded chromatin has a “beads on a string” structure (Fig. 2). The 
“string” is the DNA strand, and the “beads” are made up of the DNA “string” wrapped 
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around a histone protein core. The histone protein core consists of two molecules 
each of histones H2A, H2B, H3 and H4; the double stranded DNA wrapped around it 
is 146 bp long. This “bead” structure is referred to as the “nucleosome core particle”. 
Between the nucleosome core particles are regions of linker DNA (the “string”) of up 
to about 80 bp (Alberts et al., 2002). 
The histone core has a globular C-terminal region that connects the histones and 
binds to the DNA, and a linear N-terminal region of 20 – 36 amino acids which can be 
targeted by various types of posttranslational modifications (Fig. 4). Among these 
modifications are the acetylation and methylation of lysine and arginine, the 
phosphorylation of serine and threonine, the sumoylation and ubiquitylation of lysine 
(Spivakov and Fisher, 2007). Several types of covalent modification, such as 
acetylation and lysine methylation, are reversible. These modifications can directly 
influence the condensation and structure of chromatin and thereby influence the 
transcription of genes.  
 
 
1.3.1 Gene Regulation by Histone Modifications 
 
Histone acetylation was the first modification that was shown to regulate gene 
expression by affecting the dynamics of chromatin structure (Brownell et al., 1996). In 
1999, first evidence that histone methylation can also regulate gene expression was 
presented (Chen et al., 1999). Interestingly, the modification of a specific residue can 
lead to both gene activation and gene inactivation. For example, the acetylation of 
lysine residue 9 on Histone H3 (H3K9) is typically found in chromatin that is 
transcriptionally active, whereas H3K9 methylation is associated with a 
transcriptionally inactive state. Furthermore, specific types of modification do not 
consistently indicate activation or inactivation. The methylation of lysine 4 on histone 
H3 (H3K4), for example, is a marker for an active state of transcription. The 
methylation of lysine 27 on the same histone (H3K27), however, is a marker for an 
inactive state of transcription. Consequently, histone modifications are a versatile 
mechanism for eukaryotic cells to regulate gene expression. 
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1.3.2 Histone Methyltransferases 
 
Histone methyltransferases (HMTs) are categorized into two families: Protein 
arginine methyltransferases (PRMTs), which catalyze the transfer of methyl groups 
from SAM to arginine residues, and the SET domain family of HMTs, which are able 
to methylate lysine residues (Zhang and Reinberg, 2001).   
The three most prominent members of the SET domain family of HMTs are Suv39h1, 
Suv39h2 and G9a. The first two were identified by Jenuwein and colleagues as 
lysine-preferring mammalian HMTases in 2000, respectively (Rea et al., 2000; 
O’Carroll et al., 2000). Both were shown to selectively methylate H3K9. G9a, 
discovered by Tachibana and colleagues in 2001, also transfers methyl groups to 
H3K9, but with 10 to 20-fold higher activity than Suv39h1. Additionally, it can 
methylate lysine 27 of histone H3 (H3K27) (Tachibana et al., 2001).  
 
 
 
Figure 4. Posttranslational histone modifications  
  
Posttranslational histone modifications mostly take place on the N-terminal tails of the core 
histones H2A, H2B, H3 and H4. Here the known sites of possible acetylation, methylation, 
phosphorylation and ubiquitylation are shown. Some amino acids can be targeted by more 
than one type of modification. (Figure from Spivakov and Fisher, 2007) 
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1.4 Diseases Resulting from Epimutations 
 
Errors in the establishment or maintenance of DNA-methylation patterns and histone-
modification patterns can wrongly lead to the activation of a silent gene or the 
inactivation of an active gene (Horsthemke, 2005b). Epimutations are split into two 
groups, primary and secondary epimutations, and comprise these types of errors 
(Holliday, 1987).  
Primary epimutations are most likely to be the consequence of stochastically 
occurring errors in the composition or maintenance of the epigenetic status of a gene 
without change of the DNA sequence itself. They can occur during the deletion of 
genomic imprints in primordial germ cells, during the subsequent re-establishment of 
imprints, or after fertilization during the maintenance of imprints. The rate of 
spontaneous primary epimutations can be influenced by intrinsic (genetic) or extrinsic 
factors (Horsthemke, 2005b).  
Secondary epimutations are the consequence of mutations in the DNA sequence and 
can thus be de novo or inherited. They can influence gene expression in cis when 
they are in or close to an affected gene, or in trans when they affect the function of a 
protein that controls the gene’s epigenetic state. Secondary epimutations are known 
to be the cause for at least two diseases, the Fragile X-syndrome (FXS), caused by a 
mutation in the FMR1 gene (De Boulle et al., 1993), and Facioscapulohumeral 
muscular dystrophy (FSHD), where the copy number of the variable number tandem 
repeat D4Z4 is reduced to below 11 by deletion, in comparison to 11 – 150 copies in 
healthy individuals (Lunt et al., 1995; Lunt, 1998).  
Some types of disease have been shown to be associated with both primary and 
secondary epimutations. Among these diseases are various types of cancer and 
imprinting defects such as the Prader-Willi syndrome (PWS), the Angelman 
syndrome (AS) and the Beckwith-Wiedemann syndrome (BWS) (Buiting et al., 1995; 
Buiting et al., 2003; Walter and Paulsen, 2005). Furthermore, some diseases are 
caused by defects in the methylation machinery itself, such as the Immunodeficiency, 
Centromere instability and Facial anomalies syndrome (ICF syndrome), caused by a 
mutation in the Dnmt3b gene (Hansen et al., 1999; Jiang et al., 2005), and Systemic 
lupus erythematosus (SLE, or commonly, “lupus”), which is characterized by DNA-
hypomethylation of T lymphocyte DNA (Sekigawa et al., 2003; Sawalha and 
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Richardson, 2005). The spectrum of diseases confirms the multiple proposed roles of 
DNA methylation, including transcriptional regulation, chromosomal structure and 
chromosomal stability. 
 
 
1.4.1 Imprinting Defects in the Prader-Willi and Angelman Syndromes 
 
Imprinted genes are usually expressed either from the paternal or the maternal allele, 
with the other allele remaining silent. Aberrant methylation can change the 
expression profile of imprinted genes, so that they are expressed from neither or both 
of the alleles. Recent studies indicate that in vitro fertilization (IVF) may be a factor 
that increases the risk of imprinting defects (Hiendleder et al., 2004). 
Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are distinct 
neurogenetic disorders and the first known examples of human diseases involving 
imprinted genes. In a small subset of patients with PWS (~ 1 %) or AS (~ 2 - 4 %) the 
disease is caused by an imprinting defect, leading to aberrant methylation and 
expression of imprinted genes in the chromosomal region 15q11q13. PWS is caused 
by the loss-of-function of paternally expressed genes in this region and characterized 
by a mild to moderate mental retardation, short stature, small hands and feet, 
hypogonadism, hyperphagia, adipositas, sleep apnea and behavioral problems. A 
loss-of-function of the maternally expressed UBE3A gene causes AS, a neurogenetic 
disease characterized by mental retardation, jerky movements, lack of speech and 
friendly behavior.  
Parent-specific gene expression is regulated by an imprinting centre (IC) within 
15q11q13. It consists of two critical elements, the AS-SRO and the PWS-SRO 
(smallest region of deletion overlap). They are defined by determining the smallest 
overlapping regions of IC-deletions in PWS and AS patients. The PWS-SRO is 
responsible for post-zygotic maintenance of the paternal imprint in the early embryo 
(Bielinska et al., 2000; El-Marrii et al., 2001), whereas the AS-SRO possibly interacts 
with the PWS-SRO to establish the maternal imprint in the female germline (Buiting 
et al., 1995; Dittrich et al., 1996; Shemer et al., 2000; Perk et al., 2002; Kantor et al. 
2004a; Kantor et al., 2004b).  
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A secondary epimutation in form of a microdeletion of the IC is the cause of 
imprinting defects in 10 – 15 % of cases (Buiting et al., 1995; Saitoh et al., 1996; 
Schuffenhauer et al., 1996; Ohta et al., 1999b; Buiting et al., 2000). However, the 
majority of patients with an imprinting defect (ID), (85 – 90 %), have a primary 
epimutation without DNA sequence changes (Buiting et al., 2003). This primary 
epimutation leads to a paternal chromosome carrying a maternal imprint in ID-
patients with PWS; in ID-patients with AS the maternal chromosome carries a 
paternal imprint. In PWS patients the chromosome 15 with a primary epimutation is 
always inherited from the paternal grandmother (Buiting et al, 2003). This is probably 
due to a failure to erase the paternal grandmother’s imprint during spermatogenesis. 
In contrast, the chromosome 15 with a primary epimutation in AS patients can be 
inherited from the maternal grandfather or grandmother, indicating that the erroneous 
imprinting occurs after fertilization, and thus could be caused by an error either in the 
establishment, or in the maintenance of the maternal imprint. 
 
 
1.4.2 DNA Methylation and Cancer 
 
Alterations in the methylation pattern of DNA can play an important role in the 
development of tumors, although it is uncertain if DNA methylation alone is sufficient 
to trigger cancer development (Bestor, 2003; Lyko, 2005; Jones and Baylin, 2007). 
Tumor cells are generally characterized by global hypomethylation of the genome 
(Feinberg and Vogelstein, 1983; Ehrlich, 2002), accompanied by region-specific 
hypermethylation (Baylin et al., 1986; Robertson and Jones, 2000).  
Global hypomethylation has been linked to a reduction in genome stability, a 
hallmark of many cancers, and can occur due to the reduced availability of methyl 
group donors (Blusztajn, 1998; Lyko, 2005). Global hypomethylation has also been 
shown to induce tumorigenesis in several different mouse models (Eden et al., 2003; 
Gaudet et al., 2003; Yamada et al., 2005; Jones and Baylin, 2007).  
Apart from a few exceptions (like the aforementioned Igf2), region-specific 
hypermethylation is closely associated with epigenetic gene silencing and therefore 
effectively results in loss-of-function mutations (Jones and Baylin, 2002; Prawitt and 
Zabel, 2005).  
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It has been shown that the promoter region of tumor suppressor genes can become 
hypermethylated during tumorigenesis (Greger et al., 1989; Herman and Baylin, 
2003, Feinberg and Tycko, 2004). Among others, this has been associated with the 
transcriptional silencing of the retinoblastoma (RB) tumor suppressor gene in patients 
with retinoblastoma tumors (Greger et al., 1994). Further studies have suggested that 
de novo methylation has a causal role in the development of tumors, and that 
hypermethylation is already detectable in the earliest stages of tumor development 
(Myohanen et al., 1998; Chan et al., 2006). One in vitro study addressing the 
overexpression of Dnmt1 in murine cells indicated that hypermethylation may 
promote cell transformation (Wu et al., 1993), but a further study that transferred this 
approach into a mouse model had an embryonic lethal phenotype, so that it could not 
be used to observe the long-term effects of Dnmt1 overexpression (Biniszkiewicz et 
al., 2002). Most other studies investigating the role of DNA methylation in cancer 
examine loss-of-function by inhibition of Dnmt1 (Robert et al., 2003). Therefore, it 
remains unclear whether DNA methylation is one of the multifactorial trigger factors 
of cancer development, or if it is induced by cancer development, or both (Bestor, 
2003; Lyko, 2005; Jones and Baylin, 2007). Clearly, more gain-of-function studies, 
preferably in vivo, are necessary to elucidate this question. 
 
 
1.5 DNA Hypermethylation by Overexpression of DNA Methyltransferases 
 
DNA hypermethylation can be triggered by an overexpression of DNA 
methyltransferases due to cancer (as mentioned in 1.4.2) or genetic modification 
(Biniszkiewicz et al., 2002; Linhart et al., 2007), but is also due to the dietary 
availability of methyl group donor nutrients such as folate and choline (Blusztajn, 
1998; Kovacheva et al., 2007; Kovacheva et al., 2007). The in vivo overexpression of 
DNMTs was demonstrated for Dnmt1 (Biniszkiewicz et al., 2002) and for Dnmt3a and 
Dnmt3b (Linhart et al. 2007). Biniszkiewicz and colleagues established murine 
embryonic stem (ES) cells that overexpress Dnmt1 using a bacterial artificial 
chromosome (BAC) transgene. Their study showed that the cultured cells have an 
increased methylation of intracisternal A particles (IAPs) and an increased 
methylation of the maternal Igf2 allele that is usually unmethylated due to genomic 
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imprinting. It also showed that the methylation of the maternal allele results in an 
increase of Igf2 expression due to a shift from monoallelic to biallelic expression of 
Igf2 (Fig. 6). The developmental potency of the transgenic ES cells was investigated 
by implanting them into tetraploid blastocysts. Because tetraploid blastocysts cannot 
contribute to embryonic lineages, the composite embryos give rise to mice that are 
entirely derived from the descendants of ES cells injected into the blastocyst (Nagy et 
al., 1990; Nagy et al., 1993). The offspring of these blastocyst injections had an 
embryonic lethal phenotype, which was attributed to the consequences of Dnmt1 
overexpression.  
 
 
 
 
 
Figure 6. Summary of methylation and expression status of repetitive sequences such 
as IAP and of the imprinted genes Igf2r and Igf2 in cells with different levels of Dnmt1 
expression, as measured by Western blot analysis (shown in second column)  
 
Repetitive sequences (IAP) and imprinted genes (Igf2r, and Igf2) are subject to postzygotic 
de novo methylation, as illustrated. Repetitive IAP sequences are highly susceptible to de 
novo methylation. Igf2r is completely resistant to de novo methylation. The imprinted region 
of Igf2 and H19 becomes fully methylated at a 4-fold level of Dnmt1 expression. The 
maternal and paternal alleles of Igf2 and Igf2r are indicated. The expression levels of IAP, 
Igf2r, and Igf2 are indicated by the number of “+” signs, while a “-” sign indicates no 
expression. Monoallelic or biallelic Igf2 expression in differentiated cells is indicated as the 
percentage of total Igf2-expressing cells. Embryonic survival of the ES cell tetraploid 
blastocyst-derived mice is summarized in the last column. Symbols: , unmethylated; , 
partially methylated (low); , partially methylated (high); , methylated; oval with one dot, 
monoallelic Igf2 expression; oval with two dots, biallelic Igf2 expression. (Figure adapted 
from Biniszkiewicz et al., 2002) 
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Linhart and colleagues established transgenic mouse lines for the overexpression of 
Dnmt3a and Dnmt3b1 (Linhart et al., 2007). After crossing in the Dnmt3b1 
overexpressing line with APCMin/+ mice, which are susceptible to colon tumors, they 
observed an increase in the number and size of intestinal adenomas and 
microadenomas as well as an increase in Igf2 expression due to H19 DMD 
hypermethylation in comparison to the APCMin/+ control mice (Fig. 7). In contrast, 
there were no indications of consequences resulting from the overexpression of 
Dnmt3a, even after inbreeding with APCMin/+ mice. They also found that the secreted 
frizzled-related protein (Sfrp) genes Sfrp2, Sfrp4 and Sfrp5 were significantly de novo 
methylated in tumor samples of the Dnmt3b1 mice.  
The Sfrp genes are considered as inhibitors of the Wnt pathway, which is a key 
component of most intestinal tumors (Clevers, 2006). In contrast to Igf2 they underlie 
the conservative mechanism for epigenetic regulation, so their methylation results in 
downregulation of expression, which may have contributed to the increased number 
of tumors in the Dnmt3b1 mouse model (Caldwell et al., 2004; Suzuki et al., 2004). 
Interestingly, Sfrp2 and Sfrp5 were also hypermethylated in normal intestinal 
mucosa, indicating that de novo methylation can lead to a silencing of Sfrp genes. 
This finding supports the hypothesis that DNA methylation is a trigger factor rather 
than a consequence of transcriptional silencing in carcinogenesis (Gu et al., 2006). 
Taken together, the research on DNMTs in cancer in combination with the 
publications Biniszkiewicz and Linhart shows that the overexpression of DNMTs can 
trigger DNA hypermethylation, although certain levels of overexpression, or certain 
predispositions to hypermethylation, may be necessary for the effect to take place.  
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Figure 7. Dnmt3b1 overexpression increases the number of intestinal tumors, the size 
of colonic microadenomas and the expression of Igf2 
 
(A) Number of macroscopic colon tumors per mouse. Increased expression of Dnmt3b1 
causes a 2.2-fold increase in the number of colon tumors per mouse (11.7 ± 1 vs. 5.3 ± 0.3 
colon tumors per mouse; P < 0.0002, Mann-Whitney test). (B) The average size of colonic 
microadenomas in Dnmt3b1-expressing mice increases 1.7-fold when compared with 
controls (364 μm ± 38 vs. 211 μm ± 25 colon; P < 0.0005). Values represent mean ± SE. (C) 
Quantitation of Igf2 expression in colon tumors normalizes to β-actin expression using real-
time PCR. The relative Igf2 expression in tumors derived from Dnmt3b1 mice (2.9 ± 0.6, n = 
10) is significantly higher than Igf2 expression in control mice (1.3 ± 0.4, n = 11), P < 0.03 
Mann Whitney U-test. (Figure from Linhart et al., 2007) 
 
 
1.6 Nutritional Influences on DNA Methylation 
 
In addition to the overexpression of DNMTs, is has also been shown that nutritional 
influences in the gestational period can affect DNA hypermethylation. Investigations 
in rats have demonstrated that raising gestational availability of folate or choline 
leads to increased levels of the methyl group donor SAM, causing DNA 
hypermethylation in liver and brain (Blusztajn et al., 1998; van Engeland et al., 2003; 
Napoli et al., 2008; Kovacheva et al., 2009). Further studies showed that prenatal 
choline deficiency decreases SAM levels, but surprisingly also leads to DNA 
hypermethylation in liver and brain by upregulation of Dnmt1 (Kovacheva et al., 
2007).  
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SAM can be synthesized from the nutrients folate (in the form of 5-
methyltetrahydrofolate) and choline. The pathways of 5-methyltetrahydrofolate and 
choline are metabolically interrelated at the point that homocysteine is methylated to 
form methionine, as shown in figure 8 (Newberne and Rogers, 1986; Zeisel and 
Niculescu, 2006). Methionine is then converted to S-adenosylmethionine (SAM) by 
methionine adenosyltransferase (MAT). SAM is the active methylating agent for 
many enzymatic methylations, including the methylation of cytosines and the 
sequential methylation of phosphatidylethanolamine to form phosphatidylcholine 
(Ridgway and Vance, 1988).  
 
 
Phosphatidylcholine 
(Lecithin) 
Phosphatidylethanolamine 
Choline 
Methionine
Homocysteine
SAH 
PEMT 
CHD
MTHF
THF CH2THF 
MTHFHM
B12BHMT 
Betaine
SAM 
Methylation reactions, 
incl. DNA methylation
MAT
Figure 8. Choline, folate, and methionine metabolism are interrelated   
 
CHD: choline dehydrogenase; BHMT: betaine homocysteine methyltransferase;             
MAT: methionine adenosyltransferase; SAM: s-adenosyl-L-methionine;                       
PEMT: phosphatidylethanolamine methyltransferase; SAH: s-adenosyl-homocysteine; 
MTHF: 5-methyltetrahydrofolate; MTHFHM: 5-methyltetrahydrofolate-homocysteine 
methyltransferase; B 12, vitamin B 12; THF: tetrahydrofolate  
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1.7 Conditional Transgenes for Overexpression Based on the Cre-loxP 
Mechanism 
 
An elegant way to investigate the in vivo effect of an overexpression of a gene is to 
study transgenic animals. The analysis of overexpression becomes problematic 
when the resulting changes are lethal, especially when the transgenic animals die at 
an early stage of development. In this case, the use of a conditional transgene is a 
solution to circumvent the lethal effects of the transgene.  
Cre-loxP conditional transgene expression can be activated by crossing in a mouse 
strain that expresses the Cre recombinase. Various transgenic mouse strains which 
express constitutively or conditionally active Cre recombinase are available but the 
promoters or mechanisms that control the Cre recombinase expression differ.  
Because of this, the Cre recombinase can be expressed in specific tissues, at 
specific time points during development, or activated upon triggering by supplying the 
transgenic animals with an exogenous agent by injection, inhalation or nutritional 
supplements. By choosing the appropriate Cre recombinase transgenic mouse line 
for cross-ins with the mouse line carrying the gene of interest, the gene of interest is 
activated according to the expression of the Cre recombinase.  
The Cre-loxP mechanism originates from the coliphage P1 and encodes an efficient 
site-specific recombination system consisting of a 38 kDa protein called cyclization 
recombination (Cre) and a short asymmetric DNA sequence called loxP (locus of X-
over P1) (Sternberg and Hamilton, 1981; Abremski et al., 1983; Hoess and Abremski, 
1985). The loxP site consists of an 8 bp sequence flanked by two sets of palindromic 
13 bp sequences (Fig. 9). 
 
 
13bp 8bp 13bp 
ATAACTTCGTATA - GCATACAT -TATACGAAGTTAT 
Figure 9. Detailed structure of the loxP site 
 
The loxP site consists of an 8 bp sequence flanked by two palindromic 13 bp sequences. 
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Recombination between two loxP sites of the same orientation occurs when the sites 
are present on either supercoiled or linear DNA, and is independent of the relative 
orientation of the loxP sites on the DNA (Sauer, 1987). The recombination between 
two directly repeated sites on the same chromosome results in a deletion of the DNA 
segment lying between the sites, whereas the recombination between two sites of 
inverted orientation results in an inversion of the DNA segment between the two sites 
(Sauer and Henderson, 1988). The only factor necessary to trigger the recombination 
of loxP sites is the Cre recombinase protein. The Cre protein consists of 343 amino 
acids and is composed of four subunits and two domains. The catalytic site of the 
enzyme is the C-terminal domain, which is similar in structure to the domain in the 
Integrase family of enzymes isolated from lambda phage (Sauer, 1987).  
By flanking or “floxing” a gene region with loxP sites it is possible to target this region 
for site-specific recombination by the Cre recombinase. This mechanism can be used 
to create a conditional transgene for overexpression that is only activated when the 
cells carrying the transgene are exposed to the Cre recombinase. Two separate 
transgenic mouse strains are needed to create an in vivo mouse model for the 
conditional expression of a transgene, one carrying the Cre recombinase, and the 
other carrying the transgene with the gene of interest.  A floxed transcriptional pause 
site must be inserted between the promoter and the gene of interest for the latter 
transgene so that the expression of the gene of interest is not initially driven by the 
promoter. As in this study, a marker protein cassette can be added to the 
transcriptional pause site to facilitate the detection of the non-recombined transgene. 
Upon exposure to Cre recombinase the marker protein and transcriptional pause site 
sequences are excised and the promoter and the gene of interest are brought 
together, resulting in the expression of the gene of interest (Fig. 10).  
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Figure 10. A model experiment using the Cre-loxP Mechanism    
In the F0 Generation there are two separate mouse strains, one carrying a gene for the Cre 
recombinase (top left), and the other carrying a transgene consisting of a gene of interest 
which is preceded by a floxed marker protein (eGFP) (top right). Cross-ins from the two 
strains that carry the transgene and the Cre recombinase gene (bottom left) are subject to 
recombination in cells where both genes are present, resulting in the excision of the marker 
protein and the expression of the gene of interest. Cross-ins that do not carry the Cre 
recombinase gene continue to express the marker gene, as in the F0 generation (bottom 
right). (Figure adapted from Matthias Zepper, 2008; http://commons.wikimedia.org/wiki/File: 
CreLoxP_experiment.png, licensed under the Creative Commons Attribution ShareAlike 3.0) 
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1.8 Aim  
 
The aim of this project is to create a mouse model which conditionally overexpresses 
methyltransferases. Transgene constructs for the somatic isoform of the 
maintenance DNA methyltransferase Dnmt1, Dnmt1s, as well as the histone 
methyltransferase G9A, are to be prepared. The transgene construct should 
furthermore allow the exchange of these methyltransferases for other DNA- or 
histone-methyltransferases.   
Starting with tests on the Dnmt1 transgene before the establishment of a G9A 
transgenic line, this project focuses on the creation of a mouse model to study the 
consequences of Dnmt1 overexpression. Because previous studies have found that 
overexpression of Dnmt1 was embryonically lethal, a conditional approach using the 
Cre-loxP mechanism is adopted. The vast spectrum of Cre-recombinant mouse lines 
is expected to verify previous Dnmt1 overexpression studies using a ubiquitous 
expression and provide a basis for an analysis of the consequences of Dnmt1 
overexpression in specific tissues or during specific periods of development. Using 
this strategy, the gain-of-function Dnmt1s mouse model should provide a powerful 
tool to determine whether an overexpression of Dnmt1s alone is sufficient to trigger 
hypermethylation of susceptible parts of the genome and, if so, what the 
consequences of these epimutations are. Following previous publications, the effect 
of ubiquitous Dnmt1s overexpression on the expression of Igf2 is investigated in this 
study. Because a viable transgenic mouse model for the in vivo overexpression of 
Dnmt1 has not been reported so far, the Dnmt1s mouse model may well be a 
valuable system for the investigation of the effects of Dnmt1s overexpression in 
many fields of research.  
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2. Materials and Methods 
 
The following procedures were taken from the methods collection of Sambrook and 
Maniatis (1989), unless other sources are given as reference. 
 
2.1 Materials  
 
2.1.1 Chemicals, Enzymes, and Solutions 
 
The non-radioactive chemicals and enzymes were purchased from Biomers (Ulm) 
Boehringer Mannheim (Mannheim), Clontech (Heidelberg), Invitrogen (Karlsruhe), 
Merck (Darmstadt), New England Biolabs (NEB), Promega (Mannheim), Roth 
(Karlsruhe), Sigma (Heidelberg), Serva (Heidelberg), GibcoBRL (Eggenstein), MBI 
Fermentas (St. Leon-Rot),  Peqlab (Erlangen), BD (Heidelberg), Roche (Mannheim) 
and MWG (Ebersberg) in pro analysis quality, unless stated otherwise.  
Radioactive chemicals were purchased from Perkin-Elmer (Rodgau – Jügesheim). 
 
 
2.1.2 DNA and Protein Markers 
 
DNA Markers:  1 kb DNA ladder, Invitrogen 
   100 bp DNA ladder, Invitrogen 
   pUC19 MspI-digested, Fermentas 
   FastRuler™ DNA ladder, Low Range, Fermentas 
 
Protein Marker: PageRuler™ Plus Prestained Protein Ladder, Fermentas 
 
 
2.1.3 Oligonucleotides  
 
All oligonucleotides or primers were created with the Primer3 software (http://www-
genome.wi.mit.edu/cgibin/primer/primer3_www.cgi). The individual sequences are 
listed in the Appendix. 
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2.1.4 Plasmids 
 
pVL1393-Dnmt1s   pVL1393 vector containing the Dnmt1s sequence 
pLCMV-ECFP-loxP-FRT  Vector containing the eCFP sequence 
pEGFP-N3-∆Not   Vector containing the eGFP sequence 
pCX-FLAG-P/CAF   Vector containing the CAG promoter 
pCL-Cre    Vector for Cre-recombinase expression 
 
 
2.1.5 Bacterial Strains 
 
E. coli K12 GM2163   F-, ara-14, leuB6, fhuA31, lacY1, tsx78, glnV44, 
     galK2, galT22, mcrA, dcm-6, hisG4, rfbD1, rpsL136, 
     dam13::Tn9, xylA5, mtl-1, thi-1, mcrB1, hsdR2 
 
E. coli DH5α  F-, endA1, hsdR17, (rk-, mk+), supE44, thi-1, recA1, 
 gyrA, (Nalr), relA1, D(lacZYA-argF)U169, deoR, 
 (Φ80dlacZ∆M15) 
 
 
2.1.6 Cell Line 
 
NIH-3T3    murine fibroblast cell line     
     (ATCC 1658, adherent, DMEM) 
 
 
2.1.7 Mouse Strains 
 
C3H   used for oocyte donation, Model 025, Charles River    
C57BL/6  surrogate mother and background for the transgenic mice strains,  
       Model 027, Charles River 
CMV-Cre  activator strain for the ubiquitous activation of the transgene 
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2.1.8 Antibodies 
 
Mouse anti Dnmt1 antibody [60B1220] (Abcam, Catalog-No. ab13537) 
Mouse anti RGS(H)4 antibody, BSA-free (Qiagen, Catalog-No. 34650) 
Stabilized Goat Anti-Mouse HRP Conjugated (PIERCE, Catalog-No. 1858413) 
 
 
2.1.9 Enzymes 
 
Restriction endonucleases: 
All  restriction endonucleases were purchased from Roche (Mannheim) or New 
England Biolabs (Frankfurt am Main). 
 
Other enzymes: 
AmpliTaq Gold polymerase (Roche) 
GoTaq Green polymerase (Promega) 
T4-DNA-Ligase (Roche) 
HotstarTaq (Qiagen) 
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2.2 Methods 
 
2.2.1 General DNA and RNA Procedures 
 
2.2.1.1 Mini-Preparation of Plasmid DNA 
 
For mini-preparations of plasmid DNA, a single bacterial colony (E. coli strain DH5α 
or E. coli strain K12 GM2163) was incubated overnight in 5 ml LB with ampicillin (100 
µg/ml) at   37 °C and 250 rpm. 1.5 ml of the overnight culture were transferred to a 
1.5 ml reaction tube and pelleted for 5 min (2600 x g, 4 °C). The pellet was 
resuspended in 300 µl buffer P1 and mixed by vortexing. 300 µl buffer P2 were 
added, the sample vigorously mixed by shaking, and then incubated at RT for 3 min. 
300 µl buffer P3 were added, the sample vigorously mixed by shaking, centrifuged for 
15 min (10300 x g, 4 °C), and placed on ice immediately after centrifugation. The 
supernatant was transferred to a fresh 1.5 ml reaction tube containing 500 µl ethanol 
(100 %) and centrifuged for 20 min (16000 x g, RT). The DNA pellet was washed 
with 70 % ethanol and centrifuged for 5 min (16000 x g, RT). The supernatant was 
discarded and the pellet left to air-dry for 15 min before resuspension in 25 µl H2O.  
 
Buffer P1    10 mM  EDTA  
50 mM  Tris-HCl, pH 8,0  
100 μg/ml  RNase A 
 
Buffer P2    0.2 M   NaOH 
1 %   SDS 
 
Buffer P3    3 M   potassium acetate 
adjusted to pH 5.5 with HAc 
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2.2.1.2 Maxi-Preparation of Plasmid DNA 
 
Maxi-preparations of plasmid DNA were performed using the Plasmid Maxi Kit 
(Qiagen), strictly following the protocol for low-copy plasmids. 
 
 
2.2.1.3 Agarose Gel Electrophoresis 
 
DNA or PCR products were separated by size on 1 - 2 % (w/v) agarose gels. The 
agarose was boiled in TAE buffer, cooled at RT for 5 -10 min, and 0.4 µg/ml ethidium 
bromide (EtBr) was added. Gels were run in TAE buffer with 0.4µg/ml EtBr. 6x 
loading dye were added to the samples before application to the gel slots. The 
separation was performed at 60 V for Southern blots and at 100 − 120 V for all other 
applications. DNA Markers were used to determine the specific sizes of fragments. 
The EtBr, which intercalates into the DNA, enabled visualization of the DNA on a UV-
transilluminator with a wavelength of λ=312 nm. 
 
6x DNA Loading Dye    1.5 g  Ficoll 400 (Amersham) 
      2.5 mg Bromphenol blue (Merck) 
      2.5 mg Xylene cyanol FF (Merck) 
      200 µl  0,5M EDTA Solution 
      ad 10 ml H2O (Merck) 
 
10x TAE Buffer      48.4 g  Tris Base (Sigma) 
11.4 ml Acetic Acid (J.T. Baker) 
20 ml  0.5M EDTA Solution 
ad 1l  H2O (Merck) 
 
1 kb DNA-Ladder      50 µl  1 µg/µl 1 kb Ladder (Invitrogen) 
100 µl  6x DNA Loading Dye 
850 µl  H2O (Merck) 
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pUC19 DNA (MspI(HpaII) digested)   100 µl  0.5 µg/µl pUC19 (Fermentas) 
200 µl  6x DNA Loading Dye 
900 µl  H2O (Merck) 
 
 
2.2.1.4 Gel Extraction of DNA 
 
After electrophoresis, DNA bands were excised from the agarose gel on a UV-
transilluminator with a wavelength of λ=312 nm. The QIAquick Gel Extraction Kit or 
the MinElute Gel Extraction Kit (both Qiagen) were used to purify the DNA from the 
gel slice. The procedure was performed strictly according to the manufacturer’s 
protocol. 
 
 
2.2.1.5 Concentration Measurements of DNA and RNA in Solution 
 
The exact concentration of DNA and RNA in solution was determined by photometric 
adsorption measurements at a wavelength of λ = 260 nm and 280 nm in a ND-1000 
Spectrophotometer (NanoDrop Technologies). An OD260 = 1 corresponds to a dsDNA 
concentration of 50 µg/ml or an RNA concentration of 40 µg/ml. The ratio of OD260 to 
OD280 indicates the purity of the sample. The ratio is 1.8 for pure DNA and 2.0 for 
pure RNA.  
 
 
2.2.1.6 Restriction Digests 
 
For analytical and preparative purposes, DNA or plasmid DNA was digested in a ratio 
of 1 µg DNA / 10 U restriction enzyme in the buffer supplied by the manufacturer in a 
total volume of 20 µl, or 50 µl for the Southern Blot procedure. Digests were 
performed at 37 °C for 2 – 20 h. The volume of restriction enzyme was never above 
10 % of the total volume to prevent high glycerol concentrations from inhibiting the 
digest. 
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2.2.1.7 PCR Amplification of DNA 
 
The Polymerase Chain Reaction procedure, first described by Mullis et al. in 1986, 
was used to amplify specific regions from plasmid DNA, genomic DNA and cDNA. 
Reactions were performed in volumes of 25 or 50 µl, with either AmpliTaq Gold 
polymerase (Roche, Applied Biosystems) or GoTaq Hot Start polymerase (Promega). 
In general, each preparation contains PCR buffer (supplied with the polymerase), 
MgCl2 (if MgCl2-free buffer was used), 400-1000 nM specific 5’- und 3’-
oligonucleotides (Biomers), hereinafter referred to as “primer(s)”, 200-500 µM dNTP-
mix, 50 − 1000 ng DNA as template, and 0.1 − 0.2 U/µl polymerase. The 
thermocycler programs and specific sequences for each primer are listed in the 
Appendix.   
 
 
2.2.1.8 DNA Sequencing Procedure 
 
2.2.1.8.1 Preparation Sequencing Reactions 
 
The sequencing of cloned PCR-products was performed using the “Big Dye 
Terminator Cycle Sequencing Kit v1.1” (Applied Biosystems). A 20 µl sequencing 
reaction was prepared. The sequencing reaction and program were as follows: 
 
Table 1. Sequencing reactions
Reaction volume 20 µl
PCR-Product (200 - 500 bp) 5-10 ng
Ready Reaction Premix* 4 µl
5x BigDye Sequencing Buffer* 2.5 µl
Primer (5 µM) 2 µl
H20 (Merck) ad 20 µl
* “Big Dye Terminator Cycle Sequencing Kit v1.1” 
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Table 2. Thermocycler program for sequencing reactions
96 °C 1 min Hold 
96 °C 10 s 
55 °C 5 s 
60 °C 4 min 
                              
          25 cycles 
 
 
2.2.1.8.2 Purification of Sequencing Reactions 
 
The products from sequencing reactions were purified with sephadex columns. 
Sephadex G-50 fine (GE Healthcare) was filled into the MultiScreen 45 µl Loader 
(Millipore), transferred to a MultiScreenHTS-HV plate, and soaked in 300 µl H2O 
(Merck) per well. Excess H2O was drained by centrifugation at 2.750 rpm (Centrifuge 
5403, 16M 2-MT, Eppendorf), and the plate washed twice with 150 µl H2O (Merck). 
 
The purification of sequencing reactions was then performed as follows: 
 
Short protocol: 
-  Add 1 µl 2.2 % (w/v) SDS to each reaction, heat to 98 °C for 5 min 
-  Dilute with 20 µl H2O (Merck), transfer reactions to sephadex plate 
-  Centrifuge (5 min, 2750 rpm, Centrifuge 5403, 16M 2-MT, Eppendorf) 
-  Add 20 µl Hi-Di FormamidTM (Applied Biosystems) 
 
 
2.2.1.8.3 DNA Sequencing  
 
Purified sequencing reactions were analyzed with a 3100 Genetic Analyzer (Applied 
Biosystems). Results were analyzed with Sequencing Analysis 3.7 (Applied 
Biosystems) and Sequencher 4.5 (Gene Codes Corporation) software. 
 
Dye Set:       E (Big Dye® Kit v1.1) 
Mobility File:      DT3100POP6{BD}v2.mob 
Run Module:     Seq50_20s_6500s 
Analysis Module:    BC_3100POP6SR_seqOffFtOff.saz 
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2.2.2 Transgene Cloning 
 
The cloning of the transgenes containing the N-terminally RGS-His-tagged (amino 
acid sequence: RGSHHHHHH) murine Dnmt1s and the HA-tagged (amino acid 
sequence:  YPYDVPDYA) human G9A sequences were performed by Lothar Vaßen 
from the “Institut für Zellbiologie” (IFZ), the Institute for cell biology of the University 
Hospital, Essen. The Dnmt1s cDNA was kindly provided by S. Pradhan from New 
England Biolabs. The G9A cDNA was provided by M.S. Horwitz from the Department 
of Genome Sciences of the University of Washington School of Medicine. 
 
 
2.2.2.1 Cloning of pCAG-eGFP-loxP-RGS-His-Dnmt1s 
 
In brief, the RGS-His-tagged Dnmt1s was initially cloned into the pLCMV-eCFP-loxP 
plasmid resulting in the pLCMV-eCFP-loxP-Dnmt1s plasmid. As the eCFP marker 
protein was not easy to detect and the transgene showed no expression (data not 
shown), the eCFP region of the pLCMV-eCFP-loxP-Dnmt1s plasmid was replaced by 
the eGFP sequence of the pEGFP-N3-∆Not plasmid to facilitate the detection of the 
fluorescent marker protein. Furthermore, the CMV promoter was replaced by the 
CAG promoter from the pCX-FLAG-P/CAF plasmid in order to achieve a stronger 
ubiquitous expression of the transgene, resulting in the final version of the transgene 
plasmid pLCAG-eGFP-loxP-Dnmt1s. 
 
 
2.2.2.2 Cloning of pCAG-eGFP-loxP-HA-G9A 
 
In short, the HA-tagged G9A was initially cloned into the pLCMV-eCFP-loxP plasmid 
resulting in the pLCMV-eCFP-loxP-G9A plasmid. To replace the CMV promoter and 
eCFP sequences with the CAG promoter and eGFP sequence, respectively, the 
Dnmt1s sequence was removed from the pLCAG-eGFP-loxP-Dnmt1s plasmid from 
2.2.2.1 to create an empty pLCAG-eGFP-loxP vector. Then the G9A transgene 
sequence was cut out from the pLCMV-eCFP-loxP-G9A plasmid and was cloned into 
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the empty pLCAG-eGFP-loxP vector, resulting in the final version of the transgene 
plasmid pLCAG-eGFP-loxP-G9A. 
 
2.2.3 Bacteria 
 
2.2.3.1 Bacterial Media 
 
b-Medium  5 g Yeast extract  
   20 g Bacto-Tryptone  
   5 g MgSO4  
   adjusted to pH 7.6 with KOH 
 
LB-Medium  1 % NaCl 
   1 %  Bacto-Tryptone 
   0.5 %  Yeast extract 
   adjusted to pH 7.5 with NaOH  
 
LB-Agar  15 g/l Bacto-Agar in LB-medium 
 
TfbI Buffer  30 mM KOAc 
   100 mM RbCl 
   10 mM CaCl2 
   50 mM MnCl2 
   15 % Glycerine  
   adjusted to pH 5.8 with 0.2 M HAc 
 
TfbII Buffer  10 mM MOPS 
   75 mM CaCl2 
   10 mM RbCl2 
   15 % Glycerine 
   adjusted to pH 6.5 with KOH 
 
Ampicillin  final concentration 100 µg/ml 
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2.2.3.2 Production of Competent Bacteria 
 
Bacterial cells that can take up DNA from the surrounding medium (competent cells) 
were produced using a slightly modified version of the rubidium-chloride method 
(Maniatis et al., 1982). A single colony of the E. coli strain DH5α or E. coli strain K12 
GM2163 was incubated in 10 ml b-medium at 37 °C and 250 rpm until an OD550 of 
0.3 was reached. 5 ml of this culture were transferred into 100 ml b-medium and 
incubated at 37 °C and 250 rpm. At an OD550 of 0.48 the culture was split into four 25 
ml aliquots in pre-cooled 50 ml falcon tubes and incubated on ice for 5 min. The cells 
were then spun down at 1250 x g for 15 min at 4 °C, and the pellet was carefully 
resuspended in 10 ml ice-cold TfbI buffer. After a 90 min incubation on ice the cells 
were spun down again at 1250 x g for 15 min at 4 °C, and the pellet was 
resuspended in 1 ml ice-cold TfbII buffer. The bacterial suspension was transferred 
into ice-cold 1.5 ml reaction tubes in 100 µl aliquots, snap frozen in liquid nitrogen, 
and stored at -80 °C until further use. 
 
 
2.2.3.3 Transformation of Competent Bacteria 
 
For the transformation procedure an aliquot of competent bacteria was thawed on 
ice. 0.1 ml of competent bacteria was mixed with 1 – 10 ng of plasmid DNA and 
incubated on ice for 30 min. After incubation the mixture was heat-shocked at 42 °C 
for 2 min in a water bath and immediately placed back on ice. After addition of 500 ml 
LB-medium the samples were incubated at 37 °C for 1 h in a shaker at 300 rpm. 100 
µl of the transformation preparation were plated out on an LB-agar plate containing 
ampicillin. The remainder of the transformation preparation was briefly spun down, 
resuspended in 100 µl supernatant, and plated out on an LB-agar plate containing 
ampicillin. The plates were incubated overnight at 37 °C before picking colonies for 
preparation of plasmid DNA as described in 2.2.1.1. 
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2.2.3.4 Control of Plasmid DNA 
 
Plasmid DNA amplified by bacterial transformations was tested by digesting the DNA 
with EcoRI or NcoI restriction endonucleases for the Dnmt1s or G9A constructs, 
respectively, as described in 2.2.1.6. Digested DNA was run on an agarose gel, and 
plasmid DNA was only purified from the gel and used for further experiments if bands 
of the expected fragment sizes (Dnmt1s: 267 bp, 4005 bp, 6995 bp; G9A: 499 bp, 
1060 bp, 1517 bp, 5449 bp) were obtained. 
 
 
2.2.4 Cell Culture 
 
All cell culture media and supplements were obtained from GibcoBRL (Eggenstein). 
 
 
2.2.4.1 Cell Culture Media 
 
DMEM (Dulbecco’s Modified Eagle’s Medium) pH 7.0  
4.5 g/l  G-Glucose 
29.23 g/l  L-Glutamin 
3.7 g/l  NaHCO3
 
FCS (Fetal Calf Serum), heat inactivated 
 
Culture Medium   DMEM + 10 % FCS 
 
Trypsin/EDTA   2.0 g/l Trypsin 
     0.2 g/l EDTA 
     in PBS (pH 7.2) w/o Ca2+/Mg2+  
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2.2.4.2 Cultivation and Splitting of Cells 
 
NIH-3T3 cells were cultivated in 75 cm2 culture flasks with 12 ml culture medium at 
37 °C in an incubator at 5 % CO2 and a relative humidity of 90 %. All procedures 
were performed under a laminar flow hood. All media and reagents were autoclaved 
or sterile-filtered before use. 
Cell splitting was performed when cells had reached 70 – 90 % confluency. The 
culture medium was removed, cells washed with 10 ml PBS, and detached by 
incubation in 1 ml Trypsin/EDTA for 5 min in the incubator. Trypsin was inactivated 
by addition of 9 ml culture medium. The detached cells were transferred to a 15 ml 
Falcon tube, spun down for 5 min at 200 x g, and resuspended in 10 ml culture 
medium. Cells were split 1:10 into a new cell culture flask. Successful transfection of 
cell cultures was checked by replacing the culture medium with PBS in cultures and 
observing eGFP fluorescence under the microscope, and by western blot analysis of 
whole cell lysates with a RGS-His-tag specific antibody.   
  
 
2.2.4.3 Transient Transfection of Plasmid DNA into NIH-3T3 Murine Fibroblasts   
  with Roti-Fect 
 
Roti®-fect reagent for the liposome-mediated transfection of eukaryotic cells was 
used for transient transfection of NIH-3T3 cells with slight alterations to the supplier’s 
protocol. 20 µg of plasmid DNA was transferred into a 1.5 ml reaction tube and filled 
to 400 µl with culture medium. In a separate 1.5 ml reaction tube 90 µl of Roti®-fect 
were mixed with 310 µl culture medium. For co-transfections, 20 µg of each plasmid 
DNA was used, and the volumes of Roti®-fect and culture medium were doubled. 
Both tubes were combined and incubated for 30 min at RT. During incubation, cells 
were washed twice with PBS and 8 ml culture medium was added. After incubation, 
the DNA-Roti®-fect mixture was added to the cultures and mixed by gently tilting the 
flask. Transfected cultures were incubated for 6 h at standard conditions, washed 
once with PBS, and incubated in culture medium (without transfection reagent) for a 
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further 18 h before preparation of whole cell protein extracts. The success of the 
transfection was tested by fluorescence microscopy. 
 
 
2.2.5 Protein from Cell Culture 
 
2.2.5.1 Whole Cell Protein Extracts from Transfected Cell Cultures 
 
To obtain whole cell protein extracts, transfected cultures were washed with PBS 
before being collected in 1 ml PBS with a cell scraper. The cell suspension was 
transferred into a weighed 1.5 ml micro centrifuge tube and centrifuged in a micro 
centrifuge at 13000 rpm for 1 min. The supernatant was removed and the weight of 
the pellet determined. The pellet was then resuspended at a concentration of        
200 µg/ml in whole cell extract buffer containing protease inhibitors. Samples were 
briefly frozen on dry ice, thawed in a 45 °C water bath for 30 sec, and centrifuged at 
13000 rpm for 15 min at 4 °C. The supernatant containing the whole cell protein 
extract was transferred to a new tube and stored at -80 °C until used for further 
experiments. 
 
 
Whole Cell Extract Buffer  30 mM  Tris-HCL, pH 8 
     0.42 M  NaCl 
     0.5 mM  EDTA 
     20 %   Glycerol  
     add Protease Inhibitor Cocktail (Pierce) 
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2.2.5.2 Concentration Measurements of Whole Cell Protein Extracts   
 
The concentration of whole cell protein extracts from cell culture was performed 
using the Coomassie Plus assay reagent (Pierce). This technique was described first 
by Bradford et al. (1976) and based on the observation that the absorbance 
maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm 
to 595 nm when binding to protein occurs. According to the manufacturer’s protocol, 
the reagent was mixed by inverting the bottle and the required amount transferred to 
a 50 ml Falcon tube and left to stand to reach RT. 33 µl of each sample were added 
to 1 ml of Coomassie Plus reagent in a cuvette, inverted several times, and left to 
stand for 5 – 10 min. The cuvettes were inverted once more before being measured 
in a Spectrophotometer at OD595. If the sample OD550 was above 1.5, 33 µl of a 1:10 
dilution of the sample were measured. The OD550 of each sample was compared to a 
standard curve prepared with BSA according to Table 3. 
 
Table 3. Preparation of standard curve for protein measurements
Standard A B C D E F G H I 
c [µg/µl] 2 1.5 1 0.75 0.5 0.25 0.125 0.025 0 
H2O [µl] 0 125 325 175 325 325 325 400 400 
BSA stock 
solution* [µl] 
300 
(Stock) 
375 
(Stock) 
325 
(Stock) 
175 
(from B) 
325 
(from C)
325 
(from E) 
325 
(from F) 
100 
(from G) 
0 
 
*BSA stock solution: 2 mg/ml 
 
 
2.2.5.3 Separation of Proteins by Electrophoretic Mobility (SDS-Page)         
(according to Laemmli, 1970)  
 
Protein samples were separated electrophoretically on a 6 % denaturing SDS-
polyacrylamide gel, prepared according to table 4 in a Mini-Protean Gel chamber 
(BioRad) according to Laemmli et al. (1970). In short, 5x Protein buffer was added to 
each sample in appropriate volumes and samples were boiled at 96 °C for 5 min 
before application to the gel slot. Separation was performed in 1x SDS running buffer 
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at 15 mA until the bromphenol blue band had passed the stacking gel (~1 h). 
Separation was then performed at 20 mA until the desired separation had been 
reached (~1.5 h), using the prestained protein ladder for judgement. For 
immunological detection, the gel containing the separated proteins was transferred to 
a nylon membrane.     
 
10 % APS    10 % Ammoniumpersulfate in H2O 
 
20 % SDS    20 % SDS in H2O 
 
Lower Tris Buffer   1.5 M  Tris-HCl, pH 8.8 
 0.4 % SDS 
 
Upper Tris Buffer   0.5 M  Tris-HCl, pH 6.8 
 0.4 % SDS 
 
Rotiphorese Gel30   30 %  Acrylamide / 0.8 % Bisacrylamide 
  
4x Sample Buffer   62 mM  Tris-HCl, pH 6.8 
 2 % SDS 
 10 % Glycerine 
 5 % DTT 
 5 % ß-Mercaptoethanol 
 0.025 % Bromphenol blue 
 
10x SDS Running Buffer  1.25 M  Tris-Base 
 2 M Glycine 
 1 % SDS 
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Table 4. 6 % SDS-Polyacrylamide gel (sufficient for 2 mini-gels)
Reagent Stacking Gel Resolving Gel 
Rotiphorese Gel30 0.65 ml 1.62 ml
Lower Tris Buffer - 2 ml
Upper Tris Buffer 1.25 ml -
H2O 3.1 ml 4.38 ml
20 % SDS 25 µl 40 µl
10 % APS 25 µl 40 µl
TEMED 10 µl 20 µl
 
 
2.2.5.4 Protein Transfer and Detection (Western Blot Analysis)   
 
A semi-dry blotting chamber (BioRad) was used to transfer the separated protein 
from the polyacrylamide gel to a nylon membrane. Before transfer, all components 
(extra thick Whatman paper, nylon membrane and polyacrylamide gel with separated 
proteins) were soaked in transfer buffer for 5 min. The components were then 
stacked on the anode of the chamber in the following order: extra thick Whatman 
paper, nylon membrane (Amersham), polyacryamide gel, extra-thick Whatman 
paper. After each layer, air bubbles were removed by gently rolling over the stack 
with a Pasteur pipette. The blotting chamber was carefully closed with the cathode 
plate and the lid, and transfer was performed for 70 min at 200 mA per blot and a 
maximum current of 23 V.  
Successful transfer was confirmed by the presence of all bands of the prestained 
protein marker on the nylon membrane. After transfer the nylon membrane was 
washed once in TBS, stained in Ponceau Red solution for 2 min, and briefly washed 
in TBS to visualize protein bands to confirm the successful separation and transfer of 
the protein samples. Gels were then destained by washing 3 x 5 min in TBS-T before 
being used in the western blot. For immunological detections the non-specific binding 
sites on the nylon membrane were blocked for 1 h in blocking solution. The 
membrane was then incubated over night at 4 °C in blocking solution containing a 
mouse monoclonal primary antibody against the RGS-His-tag (Qiagen) at a dilution 
of 1:1000. The membrane was washed 4 x 5 min in TBS-T and then incubated in 
blocking solution with a horseradish-peroxidase-conjugated goat-anti-mouse 
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secondary antibody at a dilution of 1:1000 for 1 h at RT. After incubation the 
membrane was washed 4 x 5 min in TBS-T and then incubated in ECL Substrate 
(Pierce) for 5 min. The membrane was then wrapped in saran wrap and exposed to 
an x-ray film (Fuji) for 1 to 5 min, depending on signal intensity.  
 
10x Transfer Buffer  58.2 g Tris-Base 
    29.3 g Glycine 
    18.75 ml 20 % SDS 
    ad 1000 ml H2O 
 
1x Transfer Buffer  100 ml 10x Transfer Buffer 
    200 ml Methanol  
    ad 1000 ml H2O 
 
10x TBS Buffer  12.1 g/l Tris-Base 
    87.7 g/l NaCl 
    ad 1000 ml H2O 
 
1x TBS Buffer  100 ml 10x TBS Buffer 
    ad 1000 ml H2O 
 
1x TBS-T Buffer   1000 ml 1x TBS Buffer 
    500 µl Tween-20  
 
Blocking Solution  5 % Skim Milk Powder in TBS-T 
 
Ponceau Red Stain  0.1 % Ponceau Red 
    dissolved in 5 % acetic acid 
 
ECL Kit   SuperSignal West Dura Extended Duration Substrate 
    (Pierce) 
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2.2.6 Generation of Founder Mice by Pronucleus Injections 
 
Before pronucleus injections, the first 200 bp each of the promoter, the GFP, and the 
transgene regions were sequenced, as described in 2.2.1.8, to verify that all cloning 
procedures had worked correctly and that the cloned fragments were in-frame. The 
pCAG-eGFP-loxP-Dnmt1s plasmid was digested with NotI, the digested plasmid 
DNA separated by agarose gel electrophoresis without EtBr in gel or buffer. The 
8493 bp fragment containing the transgene construct was excised from the agarose 
gel and purified using the Qiaquick Gel Extraction Kit (Qiagen), strictly following the 
manufacturer’s protocol, except that the DNA was eluted in specialized pronucleus 
injection buffer provided by the "Zentrales Tierlaboratorium" (ZTL), the Central 
Animal Facility of the University Hospital, Essen. The pronucleus injections were then 
performed by Ralph Waldschütz and Wojciech Wegrzyn of the ZTL: The purified 
transgene constructs were injected into oocytes of C3H mice, and the oocytes 
implanted into C57BL/6 surrogate mother animals. The resulting transgenic offspring 
were used as founder mice and crossed back into a C57BL/6 background. 
 
 
2.2.7 Analysis of Transgenic Mouse Lines 
 
2.2.7.1 Microscopic Analysis of GFP Expression in Mouse Tail Biopsies 
 
Using a Zeiss Axioplan microscope (Zeiss), fresh tail biopsies from each mouse were 
observed for GFP fluorescence before being used for DNA preparations.  
 
 
2.2.7.2 DNA Preparation from Mouse Tail Biopsies 
 
DNA was prepared from fresh mouse tail biopsies using the EZ1 robot system 
(Qiagen) with the EZ DNA Tissue Kit (Qiagen). 190 µl buffer G2 and 10 µl     
Proteinase K were added to the mouse tails, and samples were digested over night 
at 56 °C and 800 rpm in a thermoshaker (Eppendorf). The samples were then spun 
down at 300 x g in a microcentrifuge and the supernatant was transferred to a 2 ml 
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reaction tube. Finally, the DNA was isolated, strictly following the EZ DNA Tissue Kit 
manual. 
 
 
2.2.7.3 Transgene Sequencing 
 
The transgenic sequence from a non-recombined transgenic mouse was amplified in 
two parts using PCR (primers in appendix). The amplified fragments were run on an 
agarose gel, cut out, purified using the Qiagen MinElute Gel Purification Kit and 
prepared for sequencing as described in 2.2.1.8.1 – 2.2.1.8.2. The transgene was 
then sequenced as described in 2.2.1.8.3 in at least two-fold coverage using a 
battery of primers (sequencing primers in appendix).  
 
 
2.2.7.4 Southern Blot for Analysis of Transgene Insertion 
 
2.2.7.4.1 Generation of the Southern Blot Probe 
 
The DNA probe for the Southern blot procedure was generated by PCR using 
plasmid DNA from a maxi-preparation of the pLCAG-eGFP-loxP-Dnmt1s plasmid as 
template (Tab. 5 and 6). Twelve 50 µl PCR reactions were performed to yield enough 
product for several hundred Southern blots. The PCR products were run on an 
agarose gel, excised, and purified as described in 2.2.1.3 – 2.2.1.4. The purified PCR 
product was used as hybridization probe in Southern blots for mice carrying the 
Dnmt1s transgene. 
 
Table 5. Thermocycler program for Southern blot DNA probe 
95 °C 3 min hold 
95 °C 25 s 
56 °C 25 s 
72 °C 2 min 
                              
          35 cycles 
72 °C 10 min hold 
  4 °C ∞ hold 
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Table 6. PCR reaction to generate Southern blot probe
 1 reaction [µl] 12 reactions [µl] 
H2O 33.5 402 
10x Buffer 5 60 
MgCl2 3 36 
DMSO 2.5 30 
dNTP mix [10µM each] 2 24 
Dnmt1_g_US3 [100µM]  
(Forward Primer) 0.5 6 
Dnmt1_g_LS3 [100µM] 
(Reverse Primer) 0.5 6 
AmpliTaq Gold Polymerase 1 12 
DNA Maxiprep 2 24 
Total 50  
 
 
2.2.7.4.2 Southern Blot procedure (according to Southern, 1975) 
 
4 µg DNA from mouse tail biopsies were digested overnight with EcoRI as described 
in 2.5.6. The complete digest was run on a 0.8 % agarose gel at 60 V for 5 - 6 h 
using a 1 kb ladder in the far left lane to check the running distance. After the run, a 
picture of the gel with a fluorescent ruler was made on a UV-transilluminator with a 
wavelength of λ=312 nm before cutting off the far left lane containing the 1 kb ladder. 
The gel was then denatured by gentle shaking for 30 min in denaturing solution. After 
denaturing the gel was stacked into a Southern blot according to Fig. 11 and blotted 
over night. In short, a big block, the size of an agarose gel and 4 cm high, was placed 
in a DIN A4 basin containing 800 ml 10x SSC. Three layers of Whatman paper (35 
cm x 15 cm), pre-wet in 4xSSC, were layered over the block. Air bubbles were 
removed with a glass rod after each new layer. The denatured gel was placed on top 
of the three layers of Whatman paper, and a frame of strips cut from developed x-ray 
film was laid around the gel. A nylon 66 blotting membrane (type B, positive, Fluka 
BioChemika) pre-wet in 4x SSC was placed on the gel and air bubbles were removed 
with a glass rod. Three more layers of Whatman paper (10 x 10 cm), pre-wet in 4x 
SSC, were layered over the block, removing any air bubbles with a glass rod after 
each layer. A 6 cm stack of paper towels was placed on top of the blot stack and 
weighted down with a 1 cm high block, which was the size of an agarose gel. The 
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Southern blot was left untouched for at least 16 h to ensure a complete transfer of 
the DNA from the gel to the membrane. 
 
 
Figure 11. Schematic diagram of Southern blot procedure  
The diagram illustrates the stacking procedure for the overnight blot.   
 
After the transfer, the small block, the paper towels and the three top layers of 
Whatman paper were removed, taking care not to move the gel and the membrane. 
The gel slots were marked on the membrane using a pencil. The membrane was 
then removed, washed briefly in 4x SSC and laid on a new piece of Whatman paper 
to dry with the side that had touched the gel face up. The membrane was then 
crosslinked in an autocrosslinker with 1200 x 100 µJ/cm² energy units. For 
prehybridization, a 50 ml Falcon tube was prepared by piercing the lid of the tube 
with a large needle and filling it with 5 ml of Rapid-Hyb buffer (Amersham). The blot 
was cut to fit the 50 ml Falcon tube, taking care not to cut off any transferred DNA, 
and rolled into the tube making sure the side with the bound DNA faced inwards. The 
membrane was prehybridized at 65 °C in a rotary oven in the radionuclide laboratory 
before adding the radioactively labelled probe. 
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2.2.7.4.3 Radioactive Labelling of the Southern Blot Probe 
 
The DNA probe was radioactively labelled using the Amersham MegaprimeTM DNA 
labelling system. In brief, 50 ng DNA-Probe, prepared as described in 2.2.7.3.1, were 
pipetted into a reaction tube with a screw-on cap filled to 30 µl with H2O. 5 µl primer 
solution were added and briefly mixed by pipetting before denaturation at 95 °C for 
10 min. After denaturation, the sample was placed on ice immediately and let cool for 
2 min to prevent renaturation. The sample was spun down for 1 min at 11300 x g in a 
microcentrifuge and placed back on ice. 10 µl labelling buffer were added and the 
sample mixed by pipetting. From now on all steps were carried out in the radionuclide 
lab. 2 µl Klenow enzyme and 5 µl α-32P-dCTP were added to the sample. The tube 
was placed in a pre-warmed lead container and incubated for 30 min at 37 °C. The 
probe was then purified using the Nucleotide Removal Kit (Qiagen). 500 µl buffer PN 
were added to the sample, mixed, and the solution transferred to a QiaQuick column 
in a 2 ml collection tube. The probe was bound to the column matrix by centrifugation 
at 2400 x g for 1 min. The 2 ml collection tube and its contents were discarded and 
the column placed in a new 2 ml collection tube. The column was washed twice with 
500 µl buffer PE, centrifuging at 2400 x g for 1 min each time and discarding the 2 ml 
collection tube with contents after each wash. The column was placed in a new 2 ml 
collection tube and centrifuged dry at 11300 x g for 1 min. The column was then 
transferred to a fresh 1.5 ml reaction tube, and the labelled probe eluted in 100 µl 
buffer EB at 11300 x g for 1 min. 5 µl of the labelled probe were transferred to a 1.5 
ml reaction tube with screw-on cap and measured in a scintillation counter. The rest 
of the probe was transferred to a reaction tube with screw-on cap and denatured for 
5 min at 95 °C.  
 
 
2.2.7.4.4 Southern Blot Hybridization 
 
A volume corresponding to 5*106 counts of radioactively labelled Southern blot probe 
was added to each prehybridized blot, and incubated over night at 68 °C in a rotary 
oven. On the next day, 2x SSC was prepared and pre-warmed to 65 °C in a water 
bath. The membrane was removed from the falcon tube, placed in a plastic box with 
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lid, covered with pre-warmed 2x SSC, and incubated in a water bath at 65 °C. After 
30 min the wash solution was removed and the membrane was placed on Whatman 
paper and measured with a Geiger counter (Berthold LB1210B) at 10 cm distance. If 
a value of over 70 Bq/cm² was counted, the wash procedure was repeated. As soon 
as a measurement lower than 70 Bq/cm² was made, the blots were dried on 
Whatman paper, wrapped in saran wrap, and exposed to an x-ray film in a 
developing cartridge for three days at -80 °C before developing the film. 
 
Denaturing Solution   0.25 M NaOH 
 0.6 M NaCl  
 
10x SSC    876.5 g NaCl 
     441 g Sodium citrate 
     4000 ml H2O 
     adjusted to pH 7.0 with HCL, filled to 5 l with H2O 
   
Nylon Membrane    Fluka BioChemika Blotting-Nylon 66 Membrane, 
     type B, positive 
 
Hybridization Buffer   Amersham Rapid-Hyb Buffer 
 
Radioactive Labelling Kit  Amersham MegaprimeTM DNA labelling system 
 
 
 
 
2.2.7.5 PCR Analysis of Transgene Insertion 
 
Insertion of the non-recombined transgene was verified using a PCR that amplifies a 
532 bp region specific for the transgene, spanning from 5’ end of the CAG promoter 
to the 3’ end of the eGFP marker protein sequence. The pipetting scheme and 
thermal cycler conditions are noted in the Appendix. 
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2.2.8 Crossing-in of Founder Lines with Cre-Recombinase Expressing Mouse 
Strains 
 
The six founder mice were crossed in with the CMV-Cre mouse line. The CMV-Cre 
mouse line expresses the Cre-recombinase ubiquitously and should thus trigger 
transgene recombination in all tissues.  
 
 
2.2.9 PCR Analysis of Transgene Recombination 
 
Transgene recombination was analyzed using a PCR that amplifies 1299 bp and 218 
bp regions specific for the non-recombined and recombined transgenes, respectively. 
The amplified region spans from the 5’ end of the CAG promoter to the 3’ end of the 
Dnmt1s transgene, resulting in a large product from non-recombined version of the 
transgene and a small product from recombined versions of the transgene. The 
pipetting scheme and thermal cycler conditions are noted in the Appendix. 
 
 
2.2.10 Organ Extraction from Mice for RNA and Protein Analyses 
 
Mice designated for organ extraction were euthanized using CO2. Immediately after 
extraction a small piece of each organ of 50 – 100 mg was transferred to RNAlater 
stabilization reagent (Qiagen) for RNA preparations. The rest of the tissue was snap 
frozen in liquid nitrogen for preparation of DNA or protein.   
 
 
2.2.11 RNA Expression Analyses  
 
2.2.11.1 RNA Preparation from Mouse Tissues 
 
RNA was prepared from RNAlater (Qiagen) stabilized kidney, liver and spleen tissue 
using the RNAeasy mini Kit (Qiagen). 10 mg of stabilized tissue were placed in     
600 µl RLT buffer and disrupted and homogenized using a sonicator (Heinemann) 
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with a 3 mm microtip. Each sample was exposed to a 5 sec burst at 15 % power and 
50 % duty cycle to prevent RNA shearing due to excessive sonication.  
 
 
2.2.11.2 DNase I Digest of RNA Samples 
 
To prevent false results due to DNA contamination, the RNA samples were digested 
with DNase using the RQ1 RNase-free DNase Kit (Promega), strictly following the 
manufacturer’s protocol. 
 
 
2.2.11.3 Reverse Transcriptase Reaction for Preparation of cDNA 
 
RNA samples were transcribed into cDNA using reverse transcription for RT-PCR 
verification of transgenic RNA expression and for quantitative expression analyses of 
Dnmt1 and Igf2 using TaqMan Gene Expression Assays (Applied Biosystems). 
Reactions were prepared according to table 7. The reverse transcription was 
performed in a thermal cycler (GeneAmp PCR System 2700, Applied Biosystems) in 
three steps according to table 8. 
 
Table 7. Reverse transcription 
  sample - RT control - RNA control 
RNA 1000 ng 1000 ng - 
MgCl2 Solution (25 mM)* 4 µl 4 µl 4 µl 
10x PCR Buffer II* 2 µl 2 µl 2 µl 
dGTP (10 mM)* 2 µl 2 µl 2 µl 
dATP (10 mM)* 2 µl 2 µl 2 µl 
dTTP (10 mM)* 2 µl 2 µl 2 µl 
dCTP (10 mM)* 2 µl 2 µl 2 µl 
RNase Inhibitor (5U/µl)* 1 µl 1 µl 1 µl 
Random Hexamers (50µM)* 1 µl 1 µl 1 µl 
Reverse Transcriptase (50U/µl)* 1 µl - 1 µl 
H2O (Merck) ad 20 µl ad 20 µl ad 20 µl 
  *(Applied Biosystems) 
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Table 8. Thermocycler program for cDNA preparation
21 °C 10 min Random Hexamer Binding 
42 °C 15 min Reverse Transcription 
95 °C 5 min Denaturation 
  4 °C ∞ hold 
 
 
2.2.11.4 RT-PCR for Verification of Transgenic RNA Expression 
 
To verify the expression of RNA from the Dnmt1s transgene, a 209 bp fragment 
spanning from the RGS-His-tag into the 3’ part of the transgene was amplified from 
cDNA using PCR.  
 
 
2.2.11.5 Quantitative Expression Analysis of Dnmt1 and Igf2 (TaqMan) 
 
To determine the total amount of Dnmt1 transcript (endogenous + transgenic) and 
the amount of Igf2 transcript in comparison to the amount of Gapdh transcript, 
TaqMan Gene Expression Assays (Applied Biosystems) were performed (Assay IDs 
listed in the appendix). These Assays are a special kind of PCR, in which a probe 
with two fluorophores (a reporter-fluorophore and a quencher-fluorophore) binds to 
the target sequence between the PCR primer binding sites. As long as both 
fluorophores are bound, the emission of the reporter-fluorophore is quenched by the 
quencher-fluorophore. During the elongation phase of the PCR the probe is cleaved 
from the target sequence and then degraded by the 5’ – 3’ exonuclease activity of the 
Taq DNA-polymerase. This separates the reporter fluorophore from the quencher, so 
that its emission can be detected by a laser. By comparing the emission of the target 
gene to the emission of a reference gene, the relative expression of the target gene 
can be calculated. Gapdh served as reference gene for RNA from all tissues. For 
TaqMan analyses, 1 µg of RNA was transcribed into cDNA as described in 2.2.11.3. 
The reactions were pipetted together as in Tab. 9 in a 384-well plate using an 
EPmotion pipetting robot (Qiagen). Plates were run using the program in Tab. 10 in 
an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems). The cycle 
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threshold (Ct) values of each well were exported to a text file and imported to 
Microsoft Excel for further analysis using the Delta-Delta Ct method. 
 
Table 9. TaqMan Preparations 
cDNA 300 ng
TaqMan Gene Expression Assay (20x)* 1 µl
TaqMan Gene Expression Master Mix (2x)* 10 µl
H2O ad 20 µl
* (Applied Biosystems)    
 
Table 10. TaqMan Program
50 °C 2 min hold 
95 °C 10 min hold 
95 °C 15 s 
60 °C 1 min 
 
    45 cycles 
 
 
 
2.2.12 Whole Cell Protein Extracts from Mouse Organs 
 
To obtain whole cell protein extracts from mouse organs, fresh or frozen (-80 °C) 
tissue was cut into small pieces with a scalpel and transferred to a reaction tube with 
whole cell extract buffer containing protease inhibitors at a concentration of 200 
µg/ml. For complete lysis, the solution was disrupted and homogenized using a 
sonicator (Heinemann) with a 3 mm microtip. Each sample was exposed to a 10 sec 
burst at 15 % power and 50 % duty cycle. Samples were then centrifuged at 16000 x 
g for 30 min at 4 °C to pellet any remaining debris. The supernatant containing the 
whole cell protein extract was transferred to a new tube and stored at -80 °C until 
used for further experiments. 
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3. Results 
 
Previous in vivo studies have shown that overexpression of Dnmt1 is embryonically 
lethal (Biniszkiewicz et al. 2002). In order to investigate the consequences of an 
overexpression of Dnmt1s at specific time points during development or in specific 
tissues only, conditional transgenic mouse models were created using the Cre-loxP 
system. The expression of the transgene was activated conditionally by crossing into 
mouse lines that express the Cre recombinase at specific time points during 
development or in specific tissues only. This made it possible to breed mice that are 
not subjected to the early effects of Dnmt1s overexpression and thus create an in 
vivo model to study the consequences of Dnmt1s overexpression.   
 
 
3.1 Transgene Cloning of pLCAG-eGFP-loxP-Methyltransferase 
 
To create a transgenic mouse model, the planned transgene had to be cloned and 
tested. The pVL1393 plasmid containing the murine Dnmt1s cDNA was sequenced 
to make sure that the primary material was intact and to exclude point mutations. 
Sequencing showed that the provided Dnmt1s sequence was correct and could be 
used for further cloning. The cloning of the two transgenes containing the murine 
Dnmt1s and human G9A sequences, respectively, were performed by Lothar Vaßen 
from the “Institut für Zellbiologie” (IFZ), the Institute for cell biology of the University 
Hospital, Essen. To easily distinguish between endogenous and transgenic 
methyltransferases, recognition tags were added to the N-terminal ends of each 
methyltransferase cDNA sequence. A RGS-His-tag (amino acid sequence: 
RGSHHHHHH) was added to the Dnmt1s sequence, because it has been shown that 
an N-terminal His-tag has no effect on Dnmt1 methyltransferase activity (Fatemi et 
al., 2001; Hermann et al., 2004; Goyal et al., 2006), and a hemagglutinin-tag (HA-tag; 
amino acid sequence:  YPYDVPDYA) was added to the G9A sequence.  The RGS-
His-tagged murine Dnmt1s and HA-tagged human G9A cDNA sequences were 
initially cloned into the pLCMV-eCFP-loxP plasmid resulting in pLCMV-eCFP-loxP-
Dnmt1s and pLCMV-eCFP-loxP-G9A (Fig. 12). These transgenes were successfully 
tested in vitro using transient transfection into NIH-3T3 cells to show eCFP 
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expression in the original state of the transgene and expression of the tagged 
methyltransferase protein in the recombined version. Pronucleus injections were 
performed with both transgenes, but several transgenic mouse lines showed no in 
vivo mRNA or protein expression of Dnmt1s or G9A after inbreeding with Cre-
recombinase expressing mouse lines (data not shown).  
As both the Dnmt1s and the G9A transgene showed expression in the in vitro testing, 
but neither showed in vivo expression, it was presumed that the reason for the lack of 
in vivo expression was most likely to be due to an incompatibility of the 
cytomegalovirus (CMV) promoter in the in vivo mouse model. In consequence, new 
versions of both transgenes were cloned by replacing the CMV promoter of the 
pLCMV-eCFP-loxP-Dnmt1s plasmid with a CMV early enhancer/chicken β-actin 
(CAG) promoter from the pCX-FLAG-P/CAF plasmid in order to achieve a stronger 
ubiquitous expression of the transgene (Fig. 12). At the same time, the eCFP 
sequence was replaced with an eGFP sequence pEGFP-N3-∆Not plasmid for an 
easier detection of the fluorescent protein from the non-recombined version of the 
transgene, resulting in the final version of the Dnmt1s transgene plasmid pLCAG-
eGFP-loxP-Dnmt1s (Fig. 12).  
To clone an equivalent version of the G9A transgene, the Dnmt1s sequence was 
removed from the pLCAG-eGFP-loxP-Dnmt1s plasmid to create an empty pLCAG-
eGFP-loxP vector. The G9A transgene sequence was then cut out from the pLCMV-
eCFP-loxP-G9A plasmid and cloned into the empty pLCAG-eGFP-loxP vector, 
resulting in the final version of the transgene plasmid pLCAG-eGFP-loxP-G9A.The 
re-cloning of the transgenes was performed by Lothar Vaßen from the “Institut für 
Zellbiologie” (IFZ), the Institute for cell biology of the University Hospital, Essen. The 
resulting pLCAG-eGFP-loxP-Dnmt1s and pLCAG-eGFP-loxP-G9A plasmids were 
sequenced to make sure that the promoter, the marker protein and the tagged 
methyltransferase sequences did not contain any point mutations and were in-frame. 
Sequencing analyses showed that both transgenes contained the CAG promoter 
sequence, the eGFP marker protein sequence and the tagged methyltransferase 
sequence without any point mutations or frame shifts, so that they could be used for 
further experiments. 
Although new versions of both the Dnmt1s and the G9A transgenes were cloned, this 
second attempt was initially continued with the Dnmt1s transgene only. This was 
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done to make sure that the transgene construct led to expression in vivo before 
continuing with the establishment of a G9A transgenic model.   
 
pLCMV-eCFP-loxP-Methyltransferase:  
 
 
pLCAG-eGFP-loxP-Methyltransferase: 
 
 
Figure 12.  Diagram of pLCAG-eGFP-loxP-Methyltransferase transgene re-cloning  
 
The initial pLCMV-eCFP-loxP-Methyltransferase transgene (top) was re-cloned to replace 
the CMV promoter and eCFP marker protein sequences with the CAG promoter and eGFP 
marker protein sequences, respectively, resulting in the pLCAG-eGFP-loxP-
Methyltransferase transgene (bottom). Brown box: CMV promoter sequence; blue arrows: 
loxP sites; Cyan box: eCFP cassette; red boxes: poly A termination sequences; blue box: tag 
sequence; grey box: methyltransferase sequence; yellow box: CAG promoter; green box: 
eGFP cassette. (Figure not drawn to scale) 
 
 
 
3.1.1 Restriction Digest Control of Plasmid DNA from pLCAG-eGFP-loxP-
Methyltransferase Transformations 
 
Plasmid DNA from pLCAG-eGFP-loxP-Dnmt1s and pLCAG-eGFP-loxP-G9A 
amplified by bacterial transformations was tested by digesting 1 µg of plasmid DNA 
with 20 U EcoRI or NcoI, respectively. Digested DNA was run on a 1 % agarose gel 
and the transgenes were only used for further experiments if bands of the expected 
fragment sizes (pLCAG-eGFP-loxP-Dnmt1s: 267 bp, 4005 bp, 6995 bp; pLCAG-
eGFP-loxP-G9A: 499 bp, 1060 vp, 1517 bp, 5449 bp) were obtained. Figure 13 
shows the digests of the amplified plasmid DNA containing the pLCAG-eGFP-loxP-
Dnmt1s (lane 1) and pLCAG-eGFP-loxP-G9A (lane 2) transgenes with fragments of 
the expected sizes. Further testing was performed and transgenic mouse lines were 
established using these transgenes.  
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Figure 13. Digests of Dnmt1s and G9A plasmid DNA 
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Lane 1: The digest of pLCAG-eGFP-loxP-Dnmt1s plasmid DNA 
with EcoRI resulted in fragments of the expected sizes 267 bp, 
4005 bp and 6995 bp. Lane 2: The digest of the pLCAG-eGFP-
loxP-G9A with NcoI resulted in fragments of the sizes 499 bp, 
1060 bp, 1517 bp and 5449 bp. The correct fragment sizes after 
the digest indicated an intact transgene, which was used as an 
indicator for further testing and use. M: Marker (1 kb ladder) 
 
 
3.2 The Mechanism of the Transgene 
 
The transgenes were constructed so that they initially express the eGFP marker 
protein. The eGFP sequences of the transgenes were floxed (Fig. 14 A). When the 
transgene came into contact with Cre recombinase, the loxP sites reacted with the 
Cre recombinase so that the sequence between the loxP sites were looped out, 
removed and degraded by cellular mechanisms. In the case of the transgenes in this 
study, this led to the excision of the eGFP marker protein and its polyadenylation 
signal (Fig. 14 B). Due to this deletion, the methyltransferase sequences moved 
close to the CAG promoter, resulting in the expression of methyltransferase in the 
recombined versions of the transgenes (Fig. 14 C).   
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Figure 14. Transgene recombination 
 
(A) The CAG promoter initially drove the eGFP maker protein cassette resulting in eGFP 
expression. (B) Upon recombination with Cre recombinase, the floxed eGFP sequence was 
looped out and removed. It was then degraded by cellular mechanisms, preventing its re-
insertion. (C) After the recombination event, the CAG promoter drove the methyltransferase 
cassette, resulting in expression of tagged methyltransferase. Yellow box: CAG promoter; 
blue arrows: loxP sites; green box: eGFP cassette; red boxes: poly A termination sequences; 
blue box: tag sequence; grey box: methyltransferase sequence. (Figure not drawn to scale) 
 
 
3.3 In vitro Testing of Transgene Constructs 
 
Before the transgene was brought into a mouse strain using pronucleus injections, its 
functionality was tested in cell culture to avoid the integration of a non-functional 
transgene. This was performed by transiently transfecting pLCAG-eGFP-loxP-
Dnmt1s plasmid DNA into the NIH-3T3 cell line to check for the expression of the 
eGFP marker protein from the non-recombined transgene by fluorescence 
microscopy. Co-transfection of pLCAG-eGFP-loxP-Dnmt1s plasmid DNA and pCL-
Cre plasmid DNA was performed to verify the expression of RGS-His-tagged Dnmt1s 
protein from the recombined version of the transgene. The expression of the 
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recombined version of the Dnmt1s transgene was investigated using SDS-PAGE and 
western blot techniques with an antibody specific for the RGS-His-tag of the Dnmt1s 
transgene. 
 
 
3.3.1 Transient Transfections with the pLCAG-eGFP-loxP-Dnmt1s Plasmid 
Result in eGFP Expression 
 
The single transfections of the pLCAG-eGFP-loxP-Dnmt1s plasmid were controlled 
using a fluorescence microscope with a GFP filter. Although the transfection 
efficiency was relatively low (~ 50 %), transfected cells clearly showed the expression 
of the eGFP marker protein (Fig. 15). This proved that the promoter and eGFP 
fluorescent marker protein sequences were in-frame and fully functional. 
 
    
A B 
Figure 15. eGFP expression of Dnmt1s transfection 
(A) Single transfection of NIH-3T3 cells with pLCAG-eGFP-loxP-Dnmt1s plasmid DNA 
showed eGFP fluorescence. (B) Co-transfection of NIH-3T3 cells with pLCAG-eGFP-loxP-
Dnmt1s and pCL-Cre plasmid DNA showed no eGFP fluorescence. 
 
 
3.3.2 Co-transfections of the pLCAG-eGFP-loxP-Dnmt1s Plasmid DNA with     
pCL-Cre Plasmid DNA Results in Expression of RGS-His-tagged Dnmt1s  
 
The co-transfections of the pLCAG-eGFP-loxP-Dnmt1s plasmid DNA with pCL-Cre 
plasmid DNA were also controlled using a fluorescence microscope with a GFP filter. 
The recombination of the transgene due to the presence of the Cre recombinase led 
to the looping-out and degradation of the eGFP sequence. Therefore no eGFP 
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fluorescence could be observed in co-transfected cell cultures (Fig. 15). To show that 
the tagged Dnmt1s was being expressed in the recombined cells instead of the 
eGFP marker protein, an assay on the protein level was necessary. To do this, whole 
cell lysates were prepared from the co-transfected culture dishes, separated on an 
SDS-polyacrylamide gel, and probed with an RGS-His antibody using the western 
blot procedure. Equal loading was confirmed by a Ponceau-red stain of the blotted 
membrane prior to antibody incubation. The endogenous Dnmt1s did not contain the 
RGS-His-tag, so that a band detected of Dnmt1s size (~172 kDa) with the RGS-His 
antibody gave a definite indication of the expression of RGS-His-tagged Dnmt1s from 
the recombined transgene. The western blot showed a band of the expected size in 
co-transfections with pLCAG-eGFP-loxP-Dnmt1s and pCL-Cre plasmid DNA (Fig. 16, 
lane 1 and 2), but not in single transfections with pLCAG-eGFP-loxP-Dnmt1s plasmid 
DNA (Fig. 16, lane 3). This proved that the transgene was being successfully 
recombined and, as a result, RGS-His-tagged Dnmt1s was expressed in the co-
transfected cells. It furthermore showed that the transgene did not express Dnmt1s 
until recombination with Cre recombinase had taken place, a state which would be 
referred to as a “leaky” conditional transgene. 
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Figure 16. Western blot control of in vitro expression of RGS-His-tagged Dnmt1s  
 
Western blot analysis with whole cell lysates of NIH-3T3 cells co-transfected with pLCAG-
eGFP-loxP-Dnmt1s and pCL-Cre Plasmid DNA using an RGS-His-tag specific antibody. 
Lanes 1 and 2: transfections with different amounts (80 µg and 40 µg, respectively) of 
plasmid DNA. The bands of about 172 kDa in size indicated the expression of RGS-His-
tagged Dnmt1s protein. Lane 3: The single transfection with pLCAG-eGFP-loxP-Dnmt1s 
(without pCL-Cre plasmid DNA) did not express the RGS-His-tagged Dnmt1s protein, 
showing that the transgene required recombination to express the RGS-His-tagged Dnmt1s 
and was not “leaky”. M: Marker. 
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3.4 Pronucleus Injections 
 
The pronucleus injections were performed by Ralph Waldschütz and Wojciech 
Wegrzyn of the "Zentrales Tierlaboratorium" (ZTL), the Central Animal Facility of the 
University Hospital, Essen. A total of 26 pronucleus injections in C3H mice with the 
Dnmt1s transgene were performed. The injected oocytes were transferred to 
C57BL/6 females which served as surrogate mothers. The pronucleus injections 
resulted in six transgenic mice, of which three were female and three were male 
(Tab. 11). The six transgenic animals served as founder mice for the following 
generations and were crossed back into a C57BL/6 background. 
 
Table 11: Pronucleus injection success rate 
CAG-eGFP-Dnmt1s Pronucleus Injections (f/m) 
Transgene Transgenic Wild Type  Total 
Dnmt1s 6 (3/3) 20 (11/9) 26 (14/12) 
 
 
3.4.1 Verification of Dnmt1s Transgene Sequence Integrity in vivo by DNA 
Sequencing 
 
To make sure that the Dnmt1s transgene sequence had not been exposed to 
changes such as point mutations, the transgenic sequence from a non-recombined 
transgenic mouse of line 4 was fully sequenced. For this the transgenic sequence 
was amplifies from genomic DNA in two parts, the first spanning from the CAG 
promoter to base 1929 the Dnmt1s sequence, and the second from base 1871 of the 
Dnmt1s sequence into the Dnmt1s polyadenylation sequence, with sizes of 3164 bp 
and 3299 bp, respectively. The primers for the amplification of the Dnmt1s cassette 
span over intronic sequences of the Dnmt1s gene to prevent amplification and 
sequencing of the endogenous Dnmt1s sequence. The PCR products were run on an 
agarose gel and purified using the MinElute Gel Extraction Kit (Qiagen) to remove 
any contaminants, such as primer dimers and genomic DNA, and prepared for 
sequencing as described in 2.2.1.8.1 – 2.2.1.8.2. Sequencing of the PCR amplified 
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fragments of the transgenic sequence revealed that there were no point mutations in 
any part of the transgene and that the transgenic Dnmt1s sequence was fully 
homologous to the wild type Dnmt1s sequence (sequencing data in appendix). 
 
 
3.5 The eGFP Marker Protein Expressed in vivo from the Non-recombined 
Transgene  
 
Transgenic mice that have not been crossed in with Cre recombinant mouse strains 
should carry the non-recombined version of the pLCAG-eGFP-loxP-Dnmt1s 
transgene. Therefore they should ubiquitously express the eGFP marker protein. The 
eGFP expression was controlled in this study by screening the mouse tail biopsies 
intended for genotyping with a fluorescence microscope before the isolation of DNA. 
Mouse tail biopsies showed strong expression of the eGFP marker protein (Fig. 17 A 
and B).  Fluorescence microscopy of the paws (Fig. 17 C and D), ears, nose, kidney, 
spleen and liver (data not shown) from the mice carrying the non-recombined 
transgene of lines 2 and 4 furthermore showed that the eGFP marker protein was 
also strongly expressed in those parts of the mouse. This proved that the eGFP 
marker protein was expressed in various types of mouse tissue and gave solid 
evidence that the CAG driven expression of the transgene is in fact ubiquitous. 
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Figure 17. eGFP fluorescence of tail and paw of non-recombined transgenic mice 
 
Fluorescence microscopy of mouse tails from line 2 (A) and line 4 (B) and paws from line  
2 (C) and 4 (D) of transgenic mice carrying the non-recombined transgene showed the 
expression of the eGFP marker protein.  
 
 
 
3.6 Verification of Transgene Insertion 
 
In addition to fluorescence microscopy, molecular biological methods were performed 
to prove transgene insertion in transgenic mice. In this study, PCR and Southern blot 
were the methods of choice. The PCR provided a fast screening method to 
determine which mice carried the transgene. Due to its nature however, the PCR 
method was prone to pipetting errors or contaminations which might have resulted in 
false-positive results. The PCR was also sensitive to impurities in DNA preparations 
that could have led to false-negative results. Therefore the Southern blot method 
served as a control to avoid false-positive or false-negative results, as it was more 
sensitive due to the use of a radioactively marked probe, and less prone to errors 
due to the possibility of controlling each step. During pronucleus injections, the 
number of transgene copies that inserted into the random locus could not be 
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controlled. This usually resulted in more than one copy of the transgene inserting into 
the same locus. Due to its sensitivity, the Southern blot gave a rough indication of the 
number of sequential integrations of transgene copies.  
The PCR to control transgene insertion used primers that spanned a 532 bp region 
from the eGFP cassette into the Dnmt1s sequence (Fig. 18), so that a 532 bp 
product indicated successful transgene insertion (Fig. 19). The PCR reaction was 
multiplexed with primers spanning a 295 bp region of the endogenous Rag1 gene, so 
that a 295 bp product indicated a successful PCR procedure, which largely 
eliminated (but did not completely exclude) the possibility of a false-negative result 
(Fig. 19). PCR reactions lacking the 295 bp Rag1 control fragment (Fig. 19, 3rd last 
lane) had to be repeated. All primer sequences are listed in the appendix.       
 
 
 
Figure 18. Primer positions for PCR verification of transgene insertion in founder lines 
 
The primers spanned a 532 bp region from the eGFP cassette into the Dnmt1s sequence. 
(Figure not drawn to scale) 
 
 
 
 
 
500 bp 
 
 
300 bp 
 
Figure 19. PCR verification of transgene insertion  
 
The multiplex PCR resulted in a 295 bp control fragment from the endogenous Rag1 gene, 
and a 532 bp fragment that was specific for the transgene. The 295 bp verified a successful 
PCR, while an additional 532 bp fragment verified the transgenic status of the mouse. 
Samples without the 295 bp fragment (3rd last lane) had to be repeated to exclude false-
negative results. Last lane: 100 bp DNA ladder.  
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The Southern blot procedure used a radioactively marked probe that hybridized to a 
1800 bp region spanning from bases 3 – 1803 of the Dnmt1s sequence. This 
provided a sensitive method to analyze the transgenic status of mice. To ensure that 
the restriction digest of the genomic DNA used for the Southern blot was not inhibited 
due to contaminations of the DNA preparation, the agarose gel used for separation of 
the genomic DNA for the Southern blot was controlled on a UV transilluminator (Fig. 
20). After blotting, the Dnmt1s region-specific radioactively labelled DNA probe was 
hybridized to the membrane. The transgenic status was indicated by one or more 
signals additional to those produced by the endogenous Dnmt1s (Fig. 21). The 
intensity of the Southern blot signal allowed a broad estimate of the number of 
transgene copies inserted during pronucleus injections (Fig. 21 A). Due to the 
random integration of the transgene during pronucleus injections, each mouse line 
had its own specific pattern in the Southern blot, making it possible to distinguish 
between the different transgenic lines by comparing the signal patterns in the 
Southern blot, and to determine the transgenic status. Figure 21 A shows a Southern 
blot from line 1, which has one transgene-specific signal of about 5 kb, whereas 
Southern blots with DNA from line 4 (Fig. 21 B), produced two transgene-specific 
signals, one strong signal at about 5 kb, and a weaker, smaller signal at about 3 kb.    
     
 
Figure 20. Control of restriction digests for Southern blot  
 
The successful digest of genomic DNA from mouse tail biopsies was controlled by UV 
transillumination at λ=312 nm of the gels before the Southern blot procedure. Successful 
digest was indicated by a smear of DNA ranging from ~ 20 kb to ~100 bp. 1st lane: 1 kb 
ladder 
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Figure 21. Southern blot comparison of transgenic lines 
 
Southern blot of offspring from line 1 (A) and line 4 (B). The Southern blot showed four weak 
signals for the endogenous Dnmt1s in all samples. Transgenic mice showed one (A) or more 
(B) additional signals, with varying strength, depending on the number of sequential 
insertions of the transgene. Signals from different mouse lines made it possible to distinguish 
the lines by their specific patterns (one 5 kb signal for line 1, and two signals for line 4, one 
strong 5 kb signal and one weak 3 kb signal). 
 
 
3.7 Successful Transgene Recombination after Crossing in with                  
CMV-Cre-recombinant Mouse Strains  
 
Transgenic mice carrying the non-recombined version of the Dnmt1s transgene were 
crossed in with a CMV-Cre recombinant mouse strain, a strain that ubiquitously 
expresses the Cre-recombinase under the control of the CMV promoter, to 
investigate the ubiquitous overexpression of Dnmt1s from the transgene. The 
offspring from this cross-in exhibited mendelian inheritance of both the Dnmt1s and 
the Cre-recombinase transgenes, and dams showed no signs of carrying unborn 
dead embryos. Genomic DNA from the offspring of these cross-ins was analyzed by 
PCR to determine the recombination status of the transgene, and by Southern blot 
(as in 3.6) to verify the transgenic status of the mice. 
 
 
3.7.1 PCR Verification of Transgene Recombination 
 
The PCR for the verification of transgene recombination was performed using a 
forward primer situated in the CAG promoter sequence and a reverse primer situated 
in the beginning of the Dnmt1s cassette (Fig. 22, primer sequences in appendix). By 
?5 kb ? 
3 kb ? 
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using this selection of primers, different product sizes were amplified from non-
recombined and recombined versions of the transgene. DNA from mice carrying the 
non-recombined version of the transgene bore a product that spanned from the CAG 
promoter over the eGFP cassette to the beginning of the Dnmt1s sequence, resulting 
in a product size of 1299 bp (Fig. 23, lanes 5, 6, 13 and 14). DNA from mice carrying 
only the recombined version of the transgene bore a product lacking the eGFP 
sequence due to the excision of the eGFP cassette during recombination, resulting in 
a smaller product of 218 bp (Fig. 23, lane 8). As multiple integrations of the 
transgene could occur in sequence, it was possible that not all of the copies of the 
transgene had recombined upon Cre cross-ins, and that some mice might carry both 
the non-recombined as well as the recombined version of the transgene. PCR 
amplification of DNA from those mice resulted in both the large 1299 bp fragment 
and the small 218 bp fragment (Fig. 23, lanes 3 and 10). The remainder of non-
recombined transgene copies was avoided in further breeding by choosing mice that 
exclusively had the small band in PCR analysis.  
  
 
 
 
 
Figure 22. Diagram of transgene with primer positions 
 
The primers used for the PCR to verify the transgene recombination resulted in a 1299 bp 
fragment from the non-recombined transgene (A), and in a 218 bp fragment from the 
recombined transgene (B). (figure not drawn to scale) 
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Figure 23. PCR for transgene recombination 
 
DNA from mice carrying one or more copies of the non-recombined version of the transgene 
produced a 1299 bp product (lanes 5, 6, 13 and 14). DNA from mice carrying one or more 
copies of the recombined version of the transgene produced a 218 bp fragment (lane 8). 
DNA from mice carrying multiple transgene insertions of which one or more are non-
recombined and one or more are recombined produced both the 1299 bp fragment and the 
218 bp fragment (lanes 3 and 10). M: Marker (1 kb ladder) 
  
3.8 Expression Analyses of Recombined Transgenic Offspring 
 
Mice exclusively carrying recombined copies of the Dnmt1s transgene according to 
the recombination PCR (3.7) were picked for further breeding. They were first bred 
into a C57BL/6 background to eliminate the presence of the Cre-recombinase. 
Transgenic offspring of Dnmt1s+/Cre- mice were then analyzed for Dnmt1s 
expression in comparison to wild type controls. In this way the influence of the Cre-
recombinase on the results of the analyses could be excluded. 
 
 
3.8.1 The Recombined Transgene Expression of RGS-His-tagged Dnmt1s 
mRNA 
 
Reverse transcriptase PCR (RT-PCR) analysis was performed to determine if the 
transgene expressed RGS-His-tagged Dnmt1s mRNA. To avoid detection of 
endogenous Dnmt1s mRNA, the forward primer for the RT-PCR was placed in the 
RGS-His-tag sequence, allowing only the specific amplification a 209 bp tagged 
Dnmt1s transgene sequence in combination with the reverse primer (primer 
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sequences in appendix). Because the Dnmt1s sequence of in this transgene is 
intronless, the cDNA obtained from the reverse transcription has exactly the same 
sequence as the Dnmt1s cassette in genomic DNA of transgenic animals. Therefore, 
in this study special caution had to be taken to make sure that RNA preparations 
from transgenic mice were free of genomic DNA contaminations, as both reverse 
transcribed cDNA as well as genomic DNA yield a fragment in the following PCR. 
Figure 24 shows an RT-PCR from the liver and kidney of four mice, two each from 
lines 2 and 4 (+RT), with the corresponding control reaction without reverse 
transcriptase (-RT). A RNA preparation contaminated with genomic DNA from a 
mouse that carried a non-recombined copy of the Dnmt1s transgene and did not 
express the transgenic Dnmt1s mRNA was included as an example of a false-
positive RT-PCR (Fig. 24, kidney, lane 1). The RT-PCR was repeated with all 
samples that showed contamination with genomic DNA in the –RT control after 
performing an additional DNase I digest.    
 
                                                    Liver                        Kidney 
 
   M      1     2     3     4       1     2     3     4 
+ RT 
 
 
 
 
- RT 
 
 
200 bp 
 
 
 
 
 
 
 
200 bp 
 
 
 
 
 
 
 
 
 
 
Figure 24. RT-PCR for verification transgene-specific mRNA 
 
RT-PCR of liver and kidney RNA of two mice from line 2 (samples 1 and 2) and two mice 
from line 4 (samples 3 and 4). RGS-His-tagged Dnmt1s mRNA was specifically expressed in 
liver and kidney of mice carrying the recombined version of the transgene, indicated by a 209 
bp band (samples 2 and 4). Wild type mice did not express the transgenic mRNA (sample 3). 
RNA preparations from mice carrying a non-recombined copy of the Dnmt1s transgene that 
were free from genomic DNA contamination also did not yield a product in this RT-PCR 
(liver, lane 1). However, the presence of a genomic DNA contamination, as in the kidney 
sample of mouse 1, led to a false-positive 209 bp band in the RT-PCR, but also to a 209 bp 
band in the –RT reaction (kidney, lane 1). Genomic DNA contamination of RNA preparations 
was controlled by the –RT results. +RT: complete RT reaction; -RT: control reaction without 
reverse transcriptase; M: Marker (FastRuler Low Range Ladder) 
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3.8.2 Overexpression of Dnmt1s mRNA Induced by the Recombined Transgene 
 
To investigate whether the expression of the transgenic Dnmt1s mRNA leads to an 
overexpression of Dnmt1s in total, the combined expression of endogenous and 
transgenic Dnmt1s mRNA from transgenic and sibling wild type mice was compared, 
using the ABI TaqMan assay for Dnmt1s with Gapdh as endogenous control. 
Compared to sibling wild type controls, the assay showed a significant 
overexpression of total Dnmt1s in the liver and kidney of transgenic lines 2 and line 4 
(Fig. 25 and 26), but not in the spleen of the same lines (data not shown). 
Specifically, transgenic animals from line 2 showed a ~2-fold (1.79 ± 0.45) Dnmt1s 
overexpression in liver and a ~3-fold (2.86 ± 0.74) Dnmt1s overexpression in kidney 
compared to sibling wild type controls (Fig. 25).  
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Figure 25. TaqMan analysis of Dnmt1s expression in liver and kidney of line 2  
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Quantitation of Dnmt1s expression in liver and kidney of line 2 normalized to Gapdh 
expression using real-time PCR. The relative expression in tissue from transgenic mice was 
significantly higher than in wild type controls. (n ≥ 7; P < 0.01, t- test) 
                                                                                                                            Results 
 
Transgenic mice from line 4 showed a ~ 3-fold (3.17 ± 0.65) Dnmt1s overexpression 
in liver, and a ~6-fold (6.24 ± 1.48) Dnmt1s overexpression in kidney compared to 
sibling wild type controls (Fig. 26). No significant overexpression of Dnmt1s could be 
found in the spleen, liver and kidney of transgenic animals from lines 1, 3 and 5 (data 
not shown). Transgenic animals from line 6 could not be analyzed due to the overall 
low birth-rate of transgenic and wild type offspring in this line. 
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Figure 26. TaqMan analysis of Dnmt1s expression in liver and kidney of line 4 
Quantitation of Dnmt1s expression in liver and kidney of line 4 normalized to Gapdh 
expression using real-time PCR. The relative expression in tissue from transgenic mice was 
significantly higher than in wild type controls. (n ≥ 8, P < 0.001, t-test) 
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Because the overexpression of Dnmt1s was the highest in transgenic animals from 
line 4, this line was chosen for TaqMan analysis of Dnmt1s expression in two further 
tissues: brain and testis. TaqMan analysis of the combined expression of 
endogenous and transgenic Dnmt1s mRNA in brain and testis of animals from line 4 
showed a ~5.5-fold (5.44 ± 0.39) Dnmt1s overexpression in brain and a ~3.5-fold 
(3.47 ± 0.15) Dnmt1s overexpression in testis compared to sibling wild type controls 
(Fig. 27). 
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Figure 27. TaqMan analysis of Dnmt1s expression in brain and testis of line 4 
Quantitation of Dnmt1s expression in brain and testis of line 4 normalized to Gapdh 
expression using real-time PCR. The relative expression in tissue from transgenic mice was 
significantly higher than in wild type controls. (n ≥ 5, P < 0.001, t-test) 
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3.8.3 Overexpression of Dnmt1s Protein Induced by the Recombined 
Transgene 
 
Because a significant overexpression of Dnmt1s on mRNA level caused by the 
integrated transgene could clearly be shown by TaqMan analyses, tests were carried 
out to find out whether the transgenic mRNA was translated into protein. To prove 
the specific expression of the transgenic protein, different methods were attempted, 
including western blots with an RGS-His-tag specific antibody, purification of the 
tagged Dnmt1s using a variety of Ni-NTA resins that specifically bind His-tagged 
proteins, and protein immunoprecipitations using the RGS-His-tag antibody, followed 
by western blots with a Dnmt1 antibody, or vice versa.  
Unfortunately, none of these procedures resulted in reproducible results, so that the 
translation of the transgenic Dnmt1s protein in vivo using the RGS-His-tag sequence 
could not be verified. However, an indication of the level of Dnmt1s expression can 
be obtained if a western blot with equal amounts of whole cell extracts is performed 
and the amount of Dnmt1s protein in the samples using a Dnmt1-specific antibody is 
compared to the amount of endogenous β-actin protein using a β-actin specific 
antibody.  
Due to the normalization to the endogenous protein, in this study the amount of the 
Dnmt1s protein could be compared for transgenic and wild type samples. This 
method did not specifically prove the expression of the tagged transgenic protein, as 
it was not specific for the transgenic RGS-His-tagged Dnmt1s protein, but it 
confirmed that the elevated expression of Dnmt1s mRNA also resulted in an elevated 
expression of the Dnmt1s protein.  
To compare the amount of the Dnmt1s protein in transgenic and wild type mice, the 
following steps were taken: western blots containing 40 µg of whole cell extract 
protein from the brain and testis of transgenic animals and the same amount from 
sibling wild type samples were prepared. The western blot membrane was then cut in 
half horizontally at the marker height of 70 kDA.  The upper half was then probed 
with a horseradish-peroxidase conjugated Dnmt1-specific antibody. The lower half of 
the blot was probed with a horseradish-peroxidase conjugated β-actin antibody. 
Using the enodogenous β-actin signal (~ 40 kDa) as a control for normalization, the 
intensity of the Dnmt1s-specific bands (~ 172 kDa) could be compared between wild 
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type and transgenic samples. This procedure was performed for the tissues of line 4 
that showed the highest expression of Dnmt1s according to the TaqMan analysis, 
namely kidney, brain and testis. Dnmt1s antibody binding was reproducible for brain 
and testis samples, but not for kidney samples. 
The quantitative western blot analysis of brain and testis protein from line 4 showed a 
significant overexpression of the Dnmt1s protein in both tissues of transgenic animals 
compared to sibling wild type controls (Fig. 28). Quantitation calculated a ~ 3-fold 
Dnmt1s overexpression in brain of transgenic mice and a ~ 6-fold Dnmt1s 
overexpression in testis of transgenic mice in comparison to sibling wild type controls 
(Fig. 28).    
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Figure 28. Western blot quantitation of Dnmt1s expression in brain and testis of line 4   
 
(A) Quantitation of Dnmt1s protein from brain of line 4. Comparison of Dnmt1s expression 
normalized to β-actin expression showed a ~3-fold overexpression of Dnmt1s in the brain of 
transgenic mice. (B) Quantitation of Dnmt1s protein from testis of line 4. Comparison of 
Dnmt1s expression normalized to β-actin expression showed a ~6-fold overexpression of 
Dnmt1s in the testis of transgenic mice. Quantitations were performed using the LAS-3000 
detection system (Fuji) in combination with the Fuji Multi Gauge software (V3.0) tg: 
transgenic; wt: wild type. 
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3.9 Influence of Dnmt1s Overexpression on Igf2 Expression In-vivo 
 
To analyze whether the overexpression of Dnmt1s caused a loss of imprinting and a 
resulting increase of Igf2 expression, TaqMan analyses for Igf2 with Gapdh as 
endogenous control were performed. In the case of the quantitative western blot, the 
three tissues of line 4 that showed the highest overexpression of Dnmt1s according 
to TaqMan analysis (in 3.7) were chosen for this procedure. The Igf2 expression in 
kidney (1.18 ± 0.28), brain (1.87 ± 0.77) and testis (1.03 ± 0.29) of transgenic mice 
showed no significant difference compared to sibling wild type controls (Fig. 29). This 
analysis could not confirm an influence of the overexpression of the somatic isoform 
of Dnmt1s on the expression of Igf2. 
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Figure 29. TaqMan analysis of Igf2 expression in kidney, brain and testis of line 4 
Quantitation of Igf2 expression in kidney, brain and testis of line 4 normalized to Gapdh 
expression using real-time PCR. The relative expression in tissue from transgenic mice 
showed no significant difference to wild type controls in all three tissues.  
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(n ≥ 5, P < 0.05, t-test)  
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4. Discussion  
 
This study focuses on a mouse model which conditionally overexpresses 
methyltransferases. But because the overexpression of Dnmt1 had previously been 
shown to be embryonically lethal (Biniszkiewicz et al. 2002), a conditional approach 
using the Cre-loxP mechanism was selected and transgene constructs for the 
somatic isoform of the maintenance DNA methyltransferase Dnmt1, Dnmt1s, and for 
the histone methyltransferase G9A were prepared.  
The model system was first established with the Dnmt1s transgene before the 
initiation of a G9A transgenic line, so this thesis focused on the creation of a mouse 
model to study the consequences of Dnmt1s overexpression and its effect on the 
overexpression on the expression of Igf2. This enabled verification of the results of 
the ubiquitous Dnmt1 overexpression in mice (Biniszkiewicz et al., 2002). Building on 
the research of this and other previous publications, the gain-of-function Dnmt1s 
mouse model which was created in this study, in combination with the vast spectrum 
of available Cre-recombinant mouse lines, may well provide a powerful tool to 
determine whether an overexpression of Dnmt1s alone is sufficient to trigger 
hypermethylation of susceptible parts of the genome in specific tissues or during 
specific periods of mouse development.  It is also a valuable addition to the in vitro 
studies on Dnmt1 overexpression, which until now have mainly been performed with 
respect to cancer development (Issa et al., 1993; Wu et al., 1993; Vertino et al., 
1996; Ahluwalia et al., 2001). 
 
 
4.1 Ubiquitous Dnmt1s Overexpression Levels are Mouse Line- and Tissue-
Dependent  
 
Each of the six transgenic mouse lines in this study carried the same transgene for 
Dnmt1s overexpression. TaqMan analysis demonstrated that there were strain-
specific variances in Dnmt1s transgene expression. Three of the transgenic lines 
showed no significant overexpression of Dnmt1 mRNA relative to the endogenous 
Gapdh, while different levels of significant Dnmt1 mRNA overexpression control were 
observed in transgenic lines 2 and 4 in this study. The sixth line could not be 
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analyzed due to an overall low birth rate, although it did exhibit mendelian inheritance 
of the Dnmt1s transgene.  
In detail, TaqMan analysis of lines 2 and 4 demonstrated that the transgene did not 
induce a significant Dnmt1 mRNA overexpression in the spleen. Line 2 showed low 
(but significant) levels of Dnmt1 mRNA overexpression in liver (~2-fold) and kidney 
(~3-fold). Line 4 significantly overexpressed Dnmt1 mRNA in rising amounts in the 
liver (~ 3-fold), testis (~3.5-fold), brain (~5.5-fold) and the highest amounts in kidney 
(~6-fold). According to the GeneAtlas of the Genomics institute of the Novartis 
Research Foundation (GNF) the transcription levels of the endogenous Dnmt1 are 
from lowest to highest in kidney, liver, spleen and testis (Fig. 30; Su et al., 2002).  
 
 
Figure 30: Tissue dependent mRNA expression of endogenous Dnmt1 
Black bar: median expression (me); blue bar: me x 3; red bar: me x 10                       
(© GNF; source: http://symatlas.gnf.org/deprecated/; Su et al., 2002) 
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Thus, a correlation between the tissue-dependent expression of the transgenic 
Dnmt1s and the endogenous Dnmt1 could not be found. However, the transgenic 
Dnmt1s expression in brain could not be compared to the GNF GeneAtlas 
expression profiles, as homogenized whole brain preparations were analyzed in this 
study, whereas specific areas of the brain were used to analyze the expression in the 
GNF GeneAtlas. Quantitative western blot analysis of protein expression in brain and 
testis of animals from line 4 showed ~ 3-fold overexpression of Dnmt1s in brain and ~ 
6-fold overexpression of Dnmt1s in testis in comparison to β-actin expression. These 
results confirm transgene overexpression on the protein level, but also stand in 
contrast to the tissue-dependent levels of mRNA expression in TaqMan analyses, 
which showed higher expression in brain than in testis of mice from line 4.  
The observed tissue-dependent variances in transgene overexpression must 
therefore be taken with caution, as they may be due to the comparison of the Dnmt1s 
transgene expression to endogenous genes that are regulated in a tissue-specific 
manner. As influences of Cre-recombinase expression could be excluded due to 
elimination of the Cre-recombinase gene in recombined transgenic animals by 
crossing back into a neutral C57BL/6 background, the varying degrees of transgene 
expression are likely to be caused by the transgenic approach itself.  
One reason for possible tissue-dependent expression levels could be that the 
expression of the CMV early enhancer/chicken β-actin (CAG) promoter used in the 
transgene in this study was ubiquitous, but the expression was controlled to different 
degrees depending on the type of tissue. This theory is supported by a wide range of 
publications using pronucleus injections for the creation of animals that carry a 
transgene with the CAG promoter. The ubiquitous expression of eGFP by the CAG 
promoter has been confirmed in studies with transgenic mice (Okabe et al., 1997) as 
well as transgenic rabbits (Takahashi et al., 2007), but transgene expression was not 
quantified in these studies. A second study in transgenic mice investigating the 
overexpression of eGFP under control of the CAG promoter reported ubiquitous 
expression in all tissues except erythrocytes and hair, and tissue specific differences 
in transgene expression, but these were only estimated by fluorescence microscopy, 
and no quantitation was performed (Kawamoto et al., 2000). Further studies however 
used the CAG promoter to drive a variety of transgenes in mice, and showed 
ubiquitous but tissue-dependent transgene expression in liver, kidney, spleen, brain, 
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lung, heart, muscle, dermis, epidermis, testis and oocytes (Araki et al., 1995; Sawicki 
et al., 1998; Ikeguchi et al., 2004; Wang et al., 2004). A study in rats also confirmed 
that CAG transgene expression is tissue-dependent in other species (Takeuchi et al., 
2003).  
A possible mechanism that would explain this differential expression could involve 
the CAG promoter. Although the CAG promoter is not endogenous to the mouse and 
shares no significant sequence homology with the mouse genomic reference 
sequence, it may still be regulated by silencer or enhancer elements that are present 
in the mouse cells. Consequently, the endogenous regulatory elements may also 
influence the expression of the transgene, leading to the tissue-dependent 
differences in transgene expression relative to the endogenous Gapdh control 
observed in this study.  
A more feasible explanation for the differences in overall and tissue-dependent 
expression of the transgenic lines in this study, however, is that the site of integration 
cannot be controlled using the pronucleus injection technique. The integration site 
may play a critical role in the overall and tissue-dependent degree of CAG transgene 
expression (and most likely that of transgenes using other promoters as well), 
because the expression of endogenous genes is controlled, among others, by the 
condensation of chromatin. If the transgene is inserted into a chromosomal site that 
is silenced by chromatin condensation in some or all tissues, it will not be expressed 
in those tissues: a theory that is consistent with the aforementioned publications. This 
is furthermore strongly supported by a study where transgenic mice using the CAG 
promoter to drive the poliovirus receptor were produced by pronucleus injections of a 
transgene, which showed that tissue-dependent expression can even vary between 
transgenic lines carrying identical versions of a CAG transgene (Ida-Hosonuma et al., 
2002).  This would also explain why no significant Dnmt1s overexpression could be 
observed in three of the six transgenic lines produced in this study, while two others 
showed significant Dnmt1s overexpression of varying degrees in most of the 
analyzed tissues. To furthermore increase the overexpression of Dnmt1s in these 
two lines, homozygous cross-ins could be made. An alternative hereto would be to 
try and increase Dnmt1s activity by raising the availability of the SAM precursor 
nutrients choline or folate, preferably already during embryogenesis, by feeding a 
supplemented diet during gestation. 
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4.2 Ubiquitously Overexpressing Dnmt1s Mice are Viable 
 
The transgenic offspring of mice that ubiquitously express the Dnmt1s transgene in 
this study are viable, and no obvious phenotype resulting from the Dnmt1s 
overexpression could be observed. These findings stand in contrast to the attempt to 
create a Dnmt1 transgenic mouse line, where mice with 4-fold protein levels of 
Dnmt1 had an embryonic lethal phenotype with death occurring at the latest 12.5 
days post coitum (Biniszkiewicz et al. 2002).  
The reason for this difference in results is likely to lie in the various kinds of 
transgenes used to create the Dnmt1 overexpressing lines. The transgene used in 
this study contains the cDNA sequence for the somatic form of the murine Dnmt1 
gene (Dnmt1s). The mouse line established by Biniszkiewicz and colleagues was 
created using a non-linearized BAC clone. BAC clones are produced by digesting 
genomic DNA and ligating the fragments into the BAC plasmid vector. The Dnmt1-
BAC used by Biniszkiewicz and colleagues therefore contained the whole genomic 
DNA region of the murine Dnmt1 gene plus 100 kb of upstream genomic DNA, which 
contains endogenous genes for the intercellular adhesion molecules 1, 4 and 5 
(Icam1, Icam4, Icam5), the mitochondrial ribosomal protein L4 (Mrpl4) and the 
sphingosine-1-phosphate receptor 2 (S1pr2). Furthermore, because the clone was 
not linearized prior to transfection, it also contained the BAC plasmid vector 
backbone sequences. One cannot exclude that the accompanying overexpression of 
the other endogenous genes introduced with the Dnmt1 region, or the BAC plasmid 
vector backbone sequences introduced with the transgene, may have contributed to, 
or even caused, the phenotypic events observed by Biniszkiewicz and colleagues.  
Furthermore, because the Dnmt1-BAC mouse line contained the genomic DNA of 
Dnmt1, it not only had the capability to overexpress Dnmt1s, but also the oocyte-
specific and pachytene sperm-specific isoforms of Dnmt1, Dnmt1o and Dnmt1p, 
respectively. The embryonic lethal phenotype observed by Biniszkiewicz and 
colleagues therefore may also have resulted from an overexpression of the Dnmt1o 
isoform that is not present in the transgene in this study.  
The Dnmt1o isoform is translated and enzymatically active during the erasure and re-
establishment of DNA methylation marks in the first stages of development of the 
fertilized oocyte (Carlson et al., 1992; Mertineit et al., 1998). The involvement of 
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Dnmt1p in the embryonic lethal phenotype is less likely, as Dnmt1p has not been 
shown to be expressed on the protein level so far (Trasler et al., 1992; Mertineit et 
al., 1998; Bestor, 2000). However, a causal relationship between Dnmt1p and the 
embryonic lethal phenotype cannot be excluded, as an involvement of Dnmt1p in the 
regulation of DNA methylation may be present on the RNA level, for example by 
interference of the multiple short open reading frames of Dnmt1p with translation of 
the open reading frames of Dnmt1o or Dnmt1s (Bestor, 2000).  
Although the timeframe in which the oocyte- and pachytene sperm-specific isoforms 
are transcribed is relatively small, it is nevertheless a point in development that is 
essential for the maintenance of DNA methylation of all areas of the genome, 
including imprinted regions (Bell and Felsenfeld, 2000; Lucifero et al., 2007). The 
demonstrated hypermethylation of the methylation susceptible retroviral intracisternal 
A particle (IAP) elements and the H19 DMD in the Dnmt1 overexpressing mice 
created by Biniszkiewicz and colleagues is therefore likely to have been caused by 
an excess of the Dnmt1o and/or Dnmt1p isoforms during the re-establishment of 
DNA-methylation.  
In combination with this study, it is possible that an overexpression of Dnmt1o in the 
first stages of fertilized oocyte development causes errors in the re-establishment of 
DNA-methylation, but the overexpression of Dnmt1s does not. The corresponding in 
vivo loss-of-function studies confirms this sensitivity to Dnmt1o expression levels, as 
they have shown that Dnmt1o deficient mice fail to establish correct methylation 
patterns during embryogenesis (Cirio et al., 2008 b; Toppings et al., 2008).  
Studies with heterozygous Dnmt1s knock-out mice revealed hypomethylation of T-
lymphocytes DNA in young mice that was compensated with age, suggesting 
compensatory effects in Dnmt1s expression from the remaining allele (Yung et al., 
2001; Ray et al., 2006). A recent study using siRNA-mediated knock-down of Dnmt1s 
has, however, suggested that Dnmt1s deficiency can lead to growth retardation, but 
this finding should be taken with caution as it may also be possible that the effect of 
injected siRNA was retained after implantation to affect the growth thereafter, as the 
authors themselves stated (Kurihara et al., 2008). Taken together, the results to date 
may show that the re-establishment of DNA-methylation in the fertilized oocyte might 
only be sensitive to expression levels of Dnmt1o, but not to expression levels of 
Dnmt1s, which would explain the embryonic lethal phenotype of mice in the study by 
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Biniszkiewicz and colleagues in contrast to the viable mouse model created in this 
study. To confirm this theory, the overexpression of the Dnmt1s transgene during the 
first developmental stages of the fertilized oocyte would have to be proven. 
The theory that the fertilized oocyte might only be sensitive to expression levels of 
certain DNMTs is consistent with the results of mouse lines for the overexpression of 
the de novo DNA-methyltransferases Dnmt3a and Dnmt3b1 published in 2007 
(Linhart et al. 2007). Like the transgenic line for overexpression of Dnmt1s in this 
study, neither the Dnmt3a nor the Dnmt3b1 overexpressing transgenic lines had an 
observable phenotype. Dnmt3a has been shown to be required for methylation of 
imprinted loci during gametogenesis (Kaneda et al., 2004), but even after crossing in 
with the APCMin/+ mice, a background that is susceptible to colon cancer, the 
transgenic mouse model for overexpression of Dnmt3a showed a normal phenotype. 
Effects of Dnmt3b1 overexpression could be shown after the mouse line was crossed 
in with APCMin/+ mice, but these were long-term effects as they took place during 
adult development, and could not be shown during embryonic development. 
Dnmt3b1 is not required for methylation of imprinted loci during gametogenesis 
(Kaneda et al., 2004), providing a possible explanation for the Dnmt3b1/ APCMin/+  
mouse model not showing effects in the early embryonic stages, as observed in the 
Dnmt1 model from Biniszkiewicz and colleagues. The lack of a phenotype in the 
Dnmt3a/ APCMin/+   mice again points to a sensitivity of the fertilized oocytes to which 
DNMT is overexpressed.  
In summary, these findings support the hypothesis that the re-establishment of DNA-
methylation of susceptible regions in the fertilized oocyte is sensitive to the 
overexpression of Dnmt1o, but not sensitive to overexpression of Dnmt3a, Dnmt3b1, 
and as shown in this study, of Dnmt1s. The effects of the Dnmt1s overexpression in 
this mouse model are therefore more likely to have long-term effects on imprinted 
genes or global methylation, and less likely to cause erroneous imprinting in germ 
cells or in the first developmental stages of the fertilized oocyte.  
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4.3 Influences of DNMT Overexpression on Gene Expression 
 
The upregulation of imprinted genes encoding for growth factors, such as Igf2, has 
been shown to be present in many different types of tumors. Previous studies have 
shown that Igf2 is subject to loss of imprinting which results in biallelic expression 
and the connected upregulation of Igf2 in human and murine cancers of the liver, 
breast, pancreas and colon (Ogawa et al., 1993; Rainier et al., 1993; Steenman et 
al., 1994; Moulton et al., 1996; Jirtle, 1999). The study of Dnmt1 overexpression by 
Biniszkiewicz and colleagues (Biniszkiewicz et al., 2002) as well as the study on 
Dnmt3b1 overexpression by Linhart and colleagues (Linhart et al., 2007) showed an 
influence of DNA methyltransferase overexpression on the expression of Igf2. In both 
cases, the expression of Igf2 was upregulated as a result of hypermethylation caused 
by methyltransferase overexpression. However, no direct influence of the 
overexpression of Dnmt1s on the expression of Igf2 could be confirmed in this study. 
This difference in results could be explained by the nature of the experiments 
performed to investigate Igf2 expression in the two previous studies, and might 
additionally be explained by the different site preference for de novo methylation of 
Dnmt1s and the Dnmt3 family for the Dnmt3 overexpression study.  
The study by Biniszkiewicz and colleagues investigated the effects of the Dnmt1 BAC 
transgene on methylation of the Igf2/H19 DMD in cell culture experiments, because 
their mouse model had an embryonic lethal phenotype. The cells used by 
Biniszkiewicz and colleagues were ES cells that were differentiated into neuronal 
cells using retinoic acid and leukemia inhibitory factor (LIF) because undifferentiated 
ES cells do not express Igf2 and H19 (Tucker et al., 1996). Due to the nature of the 
utilized Dnmt1-BAC transgene, the overexpression of further endogenous genes 
introduced with the genomic Dnmt1 region, or the BAC plasmid vector backbone 
sequences introduced with the non-linearized transgene, may have contributed to the 
Igf2 upregulation observed by Biniszkiewicz and colleagues. It may also be that the 
Dnmt1o and Dnmt1p isoforms that are present in the BAC transgene of the study by 
Biniszkiewicz and colleagues are not only responsible for the epigenetic 
reprogramming in the first stages of development of the fertilized oocyte, but also for 
changes in the epigenome during the differentiation of ES cells. In this case, the 
Dnmt1 isoforms expressed by the BAC transgene may have led to a methylation of 
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the H19 DMD on both alleles during the differentiation of the ES cells, preventing 
binding of a repressor, the zinc-finger protein CCCTC-binding factor (CTCF), which 
leads to an upregulation of Igf2 expression by enhancers downstream of H19 (Arney, 
2003).  
The transgenic mouse model in this study does not express the Dnmt1o and Dnmt1p 
isoforms, which would explain why changes in Igf2 expression were observed in the 
study by Biniszkiewicz and colleagues, but could not be confirmed in this study. A 
corresponding investigation of differentiating ES cells transfected with the Dnmt1s 
transgene from this study would clarify whether the suggested resistance to Dnmt1s 
overexpression is also present in differentiating ES cells, or whether it is limited to the 
phase of re-establishment of DNA-methylation in the fertilized oocyte. 
In the study by Linhart and colleagues no influence on Igf2 expression could be 
observed in mice overexpressing Dnmt3a, Dnmt3b1, or in cross-ins of Dnmt3a and 
APCMin/+ mice. Cross-ins of the Dnmt3b1 overexpressing mice with APCMin/+ mice 
resulted in increased occurrence and size of intestinal adenomas in comparison to 
APCMin/+ mice that did not overexpress Dnmt3b1. The intestinal adenomas and, more 
importantly, the non-tumor-bearing intestinal mucosa from Dnmt3b1/ APCMin/+ mice 
both showed a significant overexpression of Igf2 and a significant down-regulation of 
Sfrp2 and Sfrp5 in comparison to control APCMin/+ mice. Hypermethylation of the H19 
DMD and of the Sfrp2 and Sfrp5 promoter regions could also be detected in both 
normal intestinal mucosa and intestinal adenomas. This shows that a susceptible 
background is necessary for Dnmt3b1 overexpression to trigger an increase of Igf2 
expression and a decrease of Sfrp2 and Sfrp5 expression caused by aberrant 
methylation, whereas for Dnmt3a overexpression even a susceptible background 
does not lead to aberrant methylation. The upregulation of Igf2 expression by 
Dnmt3b1 observed in the study by Linhart and colleagues was therefore observed 
under conditions that were not present in this study. Crossing in the transgenic 
mouse model for the overexpression of Dnmt1s from this study with the colon cancer 
susceptible APCMin/+ background would clarify whether Dnmt1s overexpression could 
affect gene regulation in adult animals by aberrant methylation like Dnmt3b1, or if 
DNA-methylation in adult animals is resistant to the overexpression of Dnmt1s, as in 
the case of Dnmt3a. When performing this proposed analysis, it would be important 
to consider the different preferential sites of Dnmt1s and the Dnmt3 family for de 
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novo methylation that were found in vitro, as the regions targeted by Dnmt1s in vivo 
may also differ from the regions that were found to be differentially methylated in the 
Dnmt3b1 mouse model (Handa and Jeltsch, 2005; Goyal et al., 2006).  
In fact, this is a further possible explanation for the difference in the results observed 
for Igf2 expression between the Dnmt3b1 mouse model and the mouse model in this 
study. Less than 10 % of the CpGs in the H19 DMD and in the promoter regions of 
Sfrp2 and Sfrp5 are CpGs in the preferential CCGG context of Dnmt1s: 5 of 59 are 
CCGG in the 2.2 kb region between 2 and 4 kb upstream of the H19 start of 
transcription (Tremblay et al., 1997); 7 of 120 are CCGG in the total 5212 bp 5’ UTR 
sequence of H19, (GenBank accession no. U19619.1; Tremblay et al., 1995); 11 of 
104 are CCGG in the CpG island comprising the Sfrp2 promoter; 6 of 85 are CCGG 
in the CpG island comprising the Sfrp5 promoter. Consequently, the lack of preferred 
recognition sites for Dnmt1s (or in other words, the abundance of preferred 
recognition sites for Dnmt3b1) may be the reason why no changes in Igf2 expression 
were found in the Dnmt1s mouse model in this study, in contrast to the study with 
Dnmt3b1 mouse model. This increases the importance of choosing candidate genes 
that have as many CCGG motifs as possible when investigating cross-ins of APCMin/+ 
with the Dnmt1s strain produced in this study. The incorporation of the H19 DMD and 
the Sfrp2 and Sfrp5 promoter region CpG islands would nevertheless be important to 
verify whether the preferential sites for de novo methylation found in vitro are also 
reflected in an in vivo situation. An alternative to this approach would be to first 
analyze the Dnmt1s transgenic animals with the anti-Methylcytidin-ChIP (-on-chip) 
method to determine candidate genes.  
In summary, transfection experiments with the Dnmt1s transgene would show if 
differentiating ES cells are susceptible or resistant to Dnmt1s overexpression. 
Crossing in the Dnmt1s mouse line into the APCMin/+ background would show if 
somatic cells are susceptible to methylation by Dnmt1s, as in the case of Dnmt3b1, 
or if they are resistant to Dnmt1s methylation, as in the case of Dnmt3a. The cross-
ins would also confirm the different specificities for de novo methylation of Dnmt1s 
and Dnmt3b1 in vivo, and might even reveal genes that are targeted for de novo 
methylation by only one of the two methyltransferases.  
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4.4 Further Characterization of the Dnmt1s Overexpressing Mouse Line  
 
In this study a mouse line that conditionally overexpresses Dnmt1s was successfully 
established. Although the RT-PCR results show that the RGS-His-tagged transgenic 
Dnmt1s is specifically transcribed on mRNA level, and leads to a significant increase 
of total Dnmt1 mRNA expression, the situation is less clear on the protein level. The 
translation of the RGS-His-tagged protein could be shown during in vitro transgene 
testing using a combination of cell culture co-transfection and a western blot with an 
RGS-His-tag specific antibody. However, when various methods were attempted to 
detect the in vivo protein using the RGS-His-tag, none of these procedures resulted 
in reproducible results, so that a specific verification of the translation of the 
transgenic Dnmt1s mRNA into a protein in vivo could not be achieved. A reason for 
the failure to detect RGS-His-tagged Dnmt1 in transgenic mice may lie in the 
structure of the transgene in this study. In addition to the ATG translational start site 
before the RGS-His-tag, there is another ATG site after the tag, at the beginning of 
the Dnmt1 open reading frame. The RGS-His-tag is patented by Qiagen, and the 
“QIAexpress® Detection and Assay Handbook” (Qiagen, supplied with RGS-His-tag 
plasmids) states that “an additional (…) internal start site close to the N-terminus of 
the insert could result in overexpressed, nearly full-size protein lacking a tag”. 
Although the RGS-His-tagged Dnmt1 could be detected in cell culture testing of the 
transgene, the conditions in the mouse model created in this study are different, as 
the abundance of transgenic DNA is lower in the cells of the live animal than in cell 
culture transfections. This could explain the problems of detecting RGS-His-tagged 
Dnmt1 in transgenic mice. 
Tests using the quantitative western blot strategy with a Dnmt1s specific antibody, 
however, did successfully show that the total expression of Dnmt1s protein in 
animals carrying the recombined version of the transgene is significantly elevated in 
brain and testis in comparison to sibling wild type control animals. Although this does 
not specifically prove the translation of the transgenic Dnmt1s, it does strongly 
suggest that the transgene is also expressed on the protein level, as this is the only 
feasible explanation for the elevated Dnmt1s expression in animals carrying the 
recombined transgene measured in the quantitative western blot.  
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Before the Dnmt1s mouse model created in this study can be confirmed as fully 
validated, the functionality of the transgenic protein still needs to be addressed. If a 
phenotype in form of hypermethylation could be detected in animals carrying the 
recombined transgene, this would be an indication for the functionality of the 
transgenic protein. The proposed cross-ins into a background susceptible to 
methylation may help to find differences in methylation between Dnmt1s 
overexpressing and control animals. Comparing the in vitro methylation activity of 
protein extracts from animals carrying the recombined transgene to sibiling wild type 
control animals might be another way of verifying the functionality of the transgenic 
protein.  
A real proof for the specific functionality of the transgenic protein, however, would be 
based on testing the in vitro methyltransferase activity of an RGS-His-tag purified 
Dnmt1s protein extract, or a ChIP-Seq or ChIP-on-chip assay on DNA from highly 
overexpressing tissues of transgenic mice in comparison to sibling wild type controls. 
 
 
4.5 Focus of Future Research Using the Dnmt1s Overexpressing Mouse Line  
 
The gain-of-function Dnmt1s strain created in this study may well be a valuable 
system for the investigation of the effects of Dnmt1s overexpression in several fields 
of research, as a viable transgenic mouse model for the in vivo overexpression of 
Dnmt1 has not been reported so far.   
First, this model could give further insight on the genes that are regulated by DNA 
methylation, especially in combination with previous overexpression studies on 
Dnmt1 (Wu et al., 1993; Vertino et al., 1996; Biniszkiewicz et al., 2002; Feltus et al., 
2003). CpG islands associated with promoter regions of genes that have been found 
to be hypermethylated in these studies such as E-CAD, ER, HBA, HIC-1, H19, Igf2, 
SST or at least predicted to be hypermethylated in these study by Feltus and 
colleagues (CDX2, GRB10, TBR1, Ipf1, SIM2, GRM6, and XT3) would be a good 
choice for a candidate gene approach. Retroviral elements like Alu-repeats, Tandem 
B1-repeats or IAPs could also be analyzed for hypermethylation. Consideration of the 
amount of the reported preferential sequence of Dnmt1 for de novo methylation 
would give insight into the relevance of this in vivo. Cross-ins with a colon cancer 
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susceptible background like the APCMin/+ model, or feeding the Dnmt1s mice with an 
excess of choline or folate to increase the availability of the methyl-group donor SAM, 
could increase the chances of finding regions prone to aberrant methylation caused 
by Dnmt1s, and in addition would help to determine if Dnmt1s has the same 
promoting effect on tumorigenesis as found by Linhardt and colleagues for Dnmt3b1 
(Linhart et al., 2007).  
Second, it has been shown that Dnmt1 can repress transcription independently of its 
methyltransferase activity as well as target certain co-repressors to replication foci, 
showing that Dnmt1 does not only duplicate DNA methylation patterns, but also re-
establishes parental states of gene activity on newly replicated DNA (Fuks et al., 
2000). The Dnmt1s mouse model produced in this study may therefore also be an 
effective tool to study the co-factors that have been shown to be involved in 
methylation by Dnmt1, as in the case of the methyl-group donor SAM or the Dnmt1 
recruiting proliferating cell nuclear antigen (PCNA) (Adams et al., 1974; Chuang et 
al., 1997; Malkas, 1998; Iida et al., 2002), and to study the Dnmt1 binding co-
repressors, such as DMAP1, E2F1, HDAC1, HDAC2, LSH, MeCP2, MBD2, MBD3, 
and Rb (Rountree et al., 2000; Tatematsu et al., 2000; Robertson et al., 2000; 
Pradhan and Kim, 2002; Kimura and Shiota, 2003; Kimura et al., 2003; Liu and 
Fisher, 2004; Myant and Stancheva, 2008). It would be interesting to investigate if 
the consequences of Dnmt1s overexpression are in some way compensated by the 
regulation of one or more of these co-factors or co-repressors, and furthermore to 
analyze which of them are limiting factors in Dnmt1s mediated DNA-methylation or 
transcriptional repression, respectively.  
Third, the Dnmt1s mouse strain also provides a model system to study the 
consequences of Dnmt1s overexpression on other DNMTs. It has been reported that 
combined action of both de novo and maintenance DNA-methyltransferases is 
required for the maintenance of DNA methylation in adult mammals and the re-
establishment of genomic methylation patterns in the fertilized oocyte (Okano et al., 
1999; Robertson et al., 1999; Ratnam et al., 2002; Chen and Li, 2006; Lucifero et al., 
2007). Furthermore, the knockout of one DNMT can lead to compensation of 
methylation by the remaining DNMTs (Kim et al., 2002; Ko et al., 2005), and 
interactions within the mammalian DNMT family itself have been shown (Margot et 
al., 2003). Analysis of the effect of the overexpression of Dnmt1s on the expression 
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levels of the remaining DNMTs may provide additional information on these 
mechanisms.  
Fourth, the Dnmt1s mouse model is also suitable for analyzing the regulation of 
Dnmt1 protein levels. It has only recently been shown that proteasome-mediated 
degradation of Dnmt1s is regulated by monomethylation of Lys-142 of Dnmt1s by 
Set7, and that Set7 protein levels directly influence the availability of Dnmt1s in 
mammalian cells (Estève et al., 2009). In this respect, the analysis of expression and 
activity of Set7 in the Dnmt1s model would give insight into the question whether 
Set7 expression is coupled in vivo to the expression or the protein levels of Dnmt1s.  
Fifth, the Dnmt1s mouse model could be used to study the effect of Dnmt1s 
overexpression on histone modifications, specifically those mediated by G9A, 
Suv39h1 and Suv39h2, which have been shown to interact with DNMTs (Fuks, 2003; 
Estève et al., 2007). The analysis of acetylation of H3K9 and methylation of H3K27 in 
the Dnmt1s mouse model would clarify if this is a way of counteracting excess levels 
of Dnmt1s in vivo besides Set7 induced degradation. Vice versa, analysis of H3K9 
methylation and H3K27 acetylation could provide information on whether the 
overexpression of Dnmt1s leads to methylation changes that in turn trigger 
transcriptional silencing by histone modifications. The establishment of a mouse line 
for the overexpression of G9A, for which a transgene was prepared in this study, will 
make cross-ins possible that overexpress both Dnmt1s and G9A. This combined 
model would be particularly interesting as it would enable the study of in vivo 
interaction between Dnmt1s and G9A, which has been shown to coordinate DNA and 
histone methylation during replication. This interaction has so far only been 
demonstrated in in vitro cell culture experiments (Estève et al., 2006). 
And finally, the mouse model in this study may furthermore provide an ideal basis for 
studying the effects of long-term Dnmt1s overexpression on cancer development. 
Most studies investigating the role of Dnmt1 methylation in cancer are in vitro loss-of-
function studies by inhibition of Dnmt1 (Robert et al., 2003) probably because a 
homozygous knock-out of Dnmt1 by mutation leads to Xist upregulation by 
demethylation and an embryonic lethal phenotype (Li et al., 1992; Beard et al., 1995). 
In vivo Dnmt1s deficient models using heterozygous knock-out had no effect on 
longevity, but showed deregulation of H19, Igf2 and Igf2r genes, unstable X 
inactivation and T-lymphocyte DNA hypomethylation (Li et al., 1993; Sado et al., 
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2000; Yung et al., 2001; Ray et al., 2006). These loss-of-function studies are based 
on the finding that cancer is associated with global hypomethylation and 
hypomethylation of (proto-) oncogenes. Another important hallmark of cancer, 
however, is the hypermethylation of tumor suppressor genes. In this sense, the 
Dnmt1s mouse model may yet provide an in vivo model for certain types of cancer. 
As no long-term effects on cancer development have been observed in the Dnmt1s 
model so far, it may be necessary to cross in the mice with a cancer susceptible 
background, such as the 129S1/SvImJ (129/Sv) and 129.MOLF-Chr19 strains for 
testicular cancer (Youngren et al., 2003; Zhu et al., 2007 ), the A/J and SWR/J 
strains for lung cancer (Manenti et al., 1995; Manenti et al., 1997), the BALB/c strain 
which is sensitive to ionizing radiation-induced mammary tumors (Yu et al., 2001), or 
one of the many transgenic strains which are meanwhile available for breast cancer 
(Radisky et al., 2009).  
The mouse model for Dnmt1s overexpression will certainly also be useful in further 
areas of research that have not been addressed here. The establishment and cross-
in of the mouse line for conditional overexpression of G9A, for which a functional 
transgene was cloned in this study, could even extend the range of possible 
applications. Hopefully, some of the many epigenetic mechanisms which have not 
been understood so far will be clarified with the help of the mouse model for 
conditional overexpression of Dnmt1s created in this study.  
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5. Summary 
 
One of the epigenetic mechanisms by which gene expression is regulated is the 
methylation of DNA. Erroneous DNA methylation can cause a vast spectrum of 
diseases. A mouse model was created in this study to investigate whether the 
overexpression of the somatic form of Dnmt1, Dnmt1s, is sufficient to cause 
erroneous methylation and disease.   
A CAG promoter-driven transgene containing the Dnmt1s DNA methyltransferase 
was constructed. Transgene functionality was tested in 3T3 murine fibroblasts in cell 
culture. Because the ubiquitous overexpression of Dnmt1 has been reported to be 
embryonically lethal, a conditional transgene was constructed using the Cre-LoxP 
system. This technique allows the initial expression of the eGFP marker protein only. 
Upon cross-ins with Cre-recombinant mouse lines, the eGFP sequence is cut out and 
degraded. This leads to the expression of the Dnmt1s under control of the CAG 
promoter. To easily distinguish between endogenous and transgenic 
methyltransferase, a RGS-His-tag was added to the N-terminal end of the Dnmt1s 
transgene.  
Pronucleus injections with the Dnmt1s transgene resulted in six founder lines verified 
by PCR, Southern blot and eGFP fluorescence. Cross-ins of these founders with 
CMV-Cre mouse lines yielded viable offspring. The ubiquitous overexpression of 
Dnmt1s was investigated in cross-ins that carry the recombined version of the 
Dnmt1s transgene and express RGS-His-tagged Dnmt1 as verified by RT-PCR. 
TaqMan analyses of total Dnmt1 expression of the line with the strongest 
overexpression showed a ~ 3-fold (3.17 ± 0.65) overexpression in liver, a ~ 3.5-fold 
(3.47 ± 0.15) overexpression in testis, a ~ 5.5-fold (5.44 ± 0.39) overexpression in 
brain and a ~ 6-fold (6.24 ± 1.48) overexpression in kidney, but no overexpression in 
the spleen of CMV-Cre recombined transgenic mice in comparison to sibling wild 
type controls. Dnmt1 overexpression was confirmed on the protein level by 
quantitative western blots, which detected ~ 3-fold Dnmt1 levels in brain and ~ 6-fold 
Dnmt1 levels in testis of transgenic mice in comparison to sibling wild type controls. 
Upcoming analyses will test the in vivo functionality of the transgenic protein and the 
phenotypic consequences of Dnmt1s overexpression. 
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7. Appendix 
 
7.1 Oligonucleotides (Primers) 
 
Primers and thermocycler program for the transgene insertion PCR (2.2.7.5 / 3.6) 
 
Dnmt1s transgene - product size: 532 bp 
GFP_US_1   5‘-CCAACGAGAAGCGCGATCACATG-3‘ 
Dnmt1_rec_LS1    5‘-CCGGGAGCGAGCCTGCCGGGGAG-3‘ 
 
Rag1control fragment - product size: 295 bp
mRag1.1    5'-GCTGATGGGAAGTCAAGCGAC-3' 
mRag1.3   5'-GGGAACTGCTGAACTTTCTGTG-3' 
 
96 °C 2 min hold 
96 °C 25 s 
56 °C 25 s 
72 °C 2 min 
                              
          35 cycles 
72 °C 10 min hold 
  4 °C ∞ hold 
 
 
 
Primers for the production of the Southern blot probe (2.2.7.4.1 / 3.6)               
product size: 1800 bp 
 
Dnmt1_gU_S3   5‘-GCCAGCGCGAACAGCTCCAGCCC-3‘ 
Dnmt1_g_LS3   5‘-GATAGACCAGCTTGGTGGTGGTGGC-3‘ 
 
The PCR conditions are described in section 2.2.7.3.1. 
  
 
 
Primers and thermocycler program for the transgene recombination PCR           
(2.2.9 / 3.72) product sizes: 218 bp, 1299 bp 
 
CAG_US_1   5‘-CTGGTTATTGTGCTGTCTCATC-3‘ 
Dnmt1_rec_LS1   5‘-CCGGGAGCGAGCCTGCCGGGGAG-3‘ 
 
96 °C 2 min hold 
96 °C 25 s 
56 °C 25 s 
72 °C 2 min 
                              
          35 cycles 
72 °C 10 min hold 
  4 °C ∞ hold 
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Primers and thermocycler program for the transgene specific RT-PCR             
(2.2.11.4 / 3.8.1) product size: 209 bp 
 
HIS_RT_US2  5‘-TCATCACCATCACCATATGCC-3‘ 
PRIMER3_RT_LS  5‘-CCAAGTCACACAACTGGCTTT-3‘ 
 
96 °C 2 min hold 
96 °C 25 s 
60 °C 25 s 
72 °C 2 min 
                               
          35 cycles 
72 °C 10 min hold 
  4 °C ∞ hold 
 
 
 
Primers and thermocycler program for sequencing templates (2.2.7.3 / 3.4.1)  
 
front fragment - product size: 3164 bp 
cDNMT1_1for  5‘-CTGGTTATTGTGCTGTCTCATC-3‘ 
Dnmt1_g_LS1  5‘-CTTATCATACTTCTCAATCTGC-3‘ 
 
back fragment - product size: 3299 bp
Dnmt1_g_US2  5‘-GCTGGTCTATCAGATCTTTGAC-3‘ 
cDNMT1_6405rev  5‘-CACAGAAGTAAGGTTCCTTCA-3‘ 
 
 
96 °C 2 min hold 
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96 °C 25 s 
56 °C 25 s 
72 °C 2 min 
                              
          35 cycles 
72 °C 10 min hold 
  4 °C ∞ hold 
 
 
 
 
Primers for Transgene sequencing (3.4.1) 
 
cDNMT1_1for 5‘-CTGGTTATTGTGCTGTCTCATC-3‘ 
cDNMT1_155for 5‘-CTGTTCACCGGGGTGGTGCC-3‘ 
cDNMT1_350for 5‘-AGCCGCTACCCCGACCACAT-3‘ 
cDNMT1_425rev 5‘-TGCGCTCCTGGACGTAGCCT-3‘ 
cDNMT1_664for 5‘-GCAGCTCGCCGACCACTACC-3‘ 
cDNMT1_707rev 5‘-CGTCGCCGATGGGGGTGTTC-3‘ 
cDNMT1_797for 5‘-CTGGAGTTCGTGACCGCCGC-3‘ 
cDNMT1_946rev 5‘-CAGGGGGAGGTGTGGGAGGT-3‘ 
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cDNMT1_1200for 5‘-CCCATGGGTAGAGGTTCTCA-3‘ 
cDNMT1_1304rev 5‘-ATGGTCCGGGAGCGAGCCTG-3‘ 
cDNMT1_1568for 5‘-CCGGCCAACCTGGAGAGCAG-3‘ 
cDNMT1_1644rev 5‘-TCCTGGGTCCCCGAGGCTTG-3‘ 
cDNMT1_1792for 5‘-CGGCTGAGTCGGCTGCAGAG-3‘ 
cDNMT1_1874rev 5‘-CACAGCAGCTGCAGCACCAC-3‘ 
cDNMT1_2073for 5‘-TCCAGACCCAGGAGCCAGCC-3‘ 
cDNMT1_2119rev 5‘-GGTCTCCGTTTGGCAGCTGGA-3‘ 
cDNMT1_2421for 5‘-TCCACCTCGACCTGGTTTGATACT-3‘ 
cDNMT1_2516rev 5‘-GACAGGACACAGGTGCCCGC-3‘ 
cDNMT1_2794for 5‘-TCCTGCAAAACAATCCTGATGCTGT-3‘ 
cDNMT1_2914rev 5‘-TGGGCGTGGCGTAAGAGGGA-3‘ 
cDNMT1_3021for 5‘-TCCCTGGGACAGAGGCGAGC-3‘ 
cDNMT1_3323for 5‘-GGCGGTGAAGGAGGCAGACG-3‘ 
cDNMT1_3447rev 5‘-GCCCAAGCCAGGAGATGCGG-3‘ 
cDNMT1_3619for 5‘-ATGCGCACTGGTTCTGCGCT-3‘ 
cDNMT1_3785rev 5‘-GCCTCCCTCCATGGCCCAGT-3‘ 
cDNMT1_3798for 5‘-ACCACACTGCCTGGGGCTGA-3‘ 
cDNMT1_4005rev 5‘-CCCGGCCATCCACCTCCTCA-3‘ 
cDNMT1_4099for 5‘-TGGCTAGCCCCGTGAAACGC-3‘ 
cDNMT1_4414for 5‘-AGGGCCGCTGTACCGTGGAG-3‘ 
cDNMT1_4489rev 5‘-CGGTCAGGGCCCCCTTGTGA-3‘ 
cDNMT1_4774for 5‘-TTCGGCTGAACAACCCCGGC-3‘ 
cDNMT1_4882rev 5‘-TGTGGCAGCCTTTGGCCCAG-3‘ 
cDNMT1_5100for 5‘-TGCCTGGTCCGCATGGGCTA-3‘ 
cDNMT1_5237for 5‘-GCATGTGTTTGCGCCCCGTG-3‘ 
cDNMT1_5338rev 5‘-ATGGTTCGGAAGGGCCCCGA-3‘ 
cDNMT1_5679for 5‘-GCAGAAGGCAAGGCCTGCGA-3‘ 
cDNMT1_5786rev 5‘-CCCGTAGAGGCCAGCCCAGT-3‘ 
cDNMT1_5835for 5‘-CCCATGGGCAAGCAGGGTCG-3‘ 
cDNMT1_6025for 5‘-GCCTGCTGTCCAGTGCTCGG-3‘ 
cDNMT1_6127rev 5‘-CAGTGCACGTGGGGCTCTGG-3‘ 
cDNMT1_6405rev 5‘-CACAGAAGTAAGGTTCCTTCA-3‘ 
CAG_LS_220 5‘-GACGTCAATGGGTGGACTATTTAC-3‘ 
GFP_LS_1 5‘-AGGGCGAGGGCGATGCCACCTA-3‘ 
GFP_LS_2 5‘-CCCGTGCTGCTGCCCGACAACC-3‘ 
rec_US_100 5‘-CAGGTTCAGGGGGAGGTGTGGG-3‘ 
Dnmt1gLS1  5‘-CTTATCATACTTCTCAATCTGC-3‘ 
Dnmt1gUS2     5‘-GCTGGTCTATCAGATCTTTGAC-3‘ 
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7.2 TaqMan Gene Expression Assays (2.2.11.5 / 3.8.2 / 3.9) 
Dnmt1  TaqMan Gene Expression Assay, ID: Mm01151063_m1 
Igf2   TaqMan Gene Expression Assay, ID: Mm00439564_m1 
Gapdh  TaqMan Endogenous Control Part No.: 4352932E  
  (equivalent to Assay ID: Mm99999915_g1). 
 
 
7.3 pLCAG-eGFP-loxP-Dnmt1s Transgene Sequence (2.2.1.8 / 3.4.1) 
Legend: 
Orange:  CAG Promoter 
Light Blue:  LoxP Site 
Green:  eGFP sequence 
Dark Blue:  RGS-His-tag 
Grey:  Dnmt1s Sequence 
Black: others 
 
GGCCGCGTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGT
CATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATG
GCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGAC
GTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGG
ACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCA
AGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGC
CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGT
CATCGCTATTACCATGGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCC
ATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTG
TGCAGCGATGGGGGCGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGC
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GGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAAT
CAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGC
GGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGAGTCGCTGCGTTGCCTTC
GCCCCGTGCCCCGCTCCGCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGACTG
ACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCT
GTAATTAGCGCTTGGTTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAA
GCCTTAAAGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGGAGCGGCTCGGGG
GGTGCGTGCGTGTGTGTGTGCGTGGGGAGCGCCGCGTGCGGCCCGCGCTGC
CCGGCGGCTGTGAGCGCTGCGGGCGCGGCGCGGGGCTTTGTGCGCTCCGCG
TGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCCGCGGTGCGGGGGGG
CTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGTGAGC
AGGGGGTGTGGGCGCGGCGGTCGGGCTGTAACCCCCCCCTGCACCCCCCTC
CCCGAGTTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTGCGGGGC
GTGGCGCGGGGCTCGCCGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTG
CCGGGCGGGGCGGGGCCGCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCG
CGGCGGCCCCGGAGCGCCGGCGGCTGTCGAGGCGCGGCGAGCCGCAGCCAT
TGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCCCAAAT
CTGGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGC
GGGCGAAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTT
CGTGCGTCGCCGCGCCGCCGTCCCCTTCTCCATCTCCAGCCTCGGGGCTGCC
GCAGGGGGACGGCTGCCTTCGGGGGGGACGGGGCAGGGCGGGGTTCGGCTT
CTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTAACCATGTTCATGCCTTCT
TCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTATTGTGCTGTCTCATCATTT
TGGCAAAGAATTAGCTTATAACTTCGTATAGCATACATTATACGAAGTTATAAC
TAGTGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGATCCATCGCCACC
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCG
AGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCG
AGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGG
CAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTG
CAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTC
CGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGAC
GGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTG
AACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGG
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GGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGA
CAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAG
GACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGC
GACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCC
TGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGT
GACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGC
CGGCCGCGACTCTAGAGGATCATAATCAGCCATACCACATTTGTAGAGGTTTT
ACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGA
ATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAG
CAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGT
GGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCTGAATTCATAAC
TTCGTATAGCATACATTATACGAAGTTATAGGATCCGAAGTTCCTATTCTCTAG
AAAGTATAGGAACTTCCCCATGGGTAGAGGTTCTCATCATCACCATCACCATA
TGCCAGCGCGAACAGCTCCAGCCCGAGTGCCTGCGCTTGCCTCCCCGGCAGG
CTCGCTCCCGGACCATGTCCGCAGGCGGCTCAAAGACTTGGAAAGAGATGGC
TTAACAGAAAAGGAGTGTGTGAGGGAGAAATTAAACTTACTGCATGAATTCCT
GCAAACAGAAATAAAAAGCCAGTTGTGTGACTTGGAAACCAAATTACATAAAG
AGGAATTATCTGAGGAAGGCTACCTGGCTAAAGTCAAGTCCCTCTTAAATAAG
GATTTGTCCTTGGAGAACGGAACACACACTCTCACTCAAAAAGCCAACGGTTG
TCCCGCCAACGGGAGCCGGCCAACCTGGAGAGCAGAAATGGCAGACTCAAA
TAGATCCCCAAGATCCAGGCCCAAGCCTCGGGGACCCAGGAGAAGCAAGTC
GGACAGTGACACCCTTTTTGAAACTTCACCTAGTTCCGTGGCTACGAGGAGAA
CCACCAGGCAGACCACCATCACGGCTCACTTCACGAAGGGCCCCACTAAACG
GAAACCCAAGGAAGAGTCGGAAGAGGGGAACTCGGCTGAGTCGGCTGCAGA
GGAGAGAGACCAGGATAAGAAACGCAGAGTTGTAGACACAGAGAGTGGTGC
TGCAGCTGCTGTGGAGAAACTGGAAGAGGTAACAGCGGGAACCCAGCTGGGT
CCGGAAGAGCCATGTGAACAGGAAGATGACAACAGGAGTCTTCGACGTCACA
CCAGAGAGCTATCATTGAGGCGGAAATCAAAGGAGGATCCAGACAGAGAAGC
AAGACCGGAAACTCACTTGGACGAGGACGAGGACGGAAAAAAGGATAAAAG
AAGTTCCAGACCCAGGAGCCAGCCCAGAGATCCAGCTGCCAAACGGAGACC
CAAGGAAGCAGAGCCAGAGCAGGTAGCTCCAGAGACTCCCGAGGACAGAGA
CGAGGATGAGAGGGAGGAGAAGAGACGAAAAACGACACGTAAAAAACTGGA
GTCACACACCGTTCCCGTTCAGAGCAGATCGGAGAGAAAAGCCGCTCAAAGC
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AAAAGTGTGATCCCGAAGATCAACTCACCAAAGTGCCCCGAGTGTGGCCAGC
ACCTAGACGACCCTAACCTGAAGTACCAGCAGCACCCTGAGGATGCTGTGGA
TGAACCCCAGATGTTGACCAGTGAGAAACTGTCCATCTACGACTCCACCTCGA
CCTGGTTTGATACTTATGAAGATTCTCCCATGCATAGGTTCACTTCCTTCAGTG
TGTACTGCAGTCGCGGGCACCTGTGTCCTGTCGACACCGGTCTCATTGAGAAG
AATGTAGAGCTCTACTTTTCTGGGTGTGCCAAAGCAATTCATGACGAGAATCC
ATCTATGGAAGGTGGTATTAATGGCAAAAACCTCGGGCCAATCAATCAGTGGT
GGCTCAGTGGCTTTGATGGTGGCGAGAAGGTGCTCATTGGCTTCTCCACTGCA
TTTGCTGAATACATTTTGATGGAGCCCAGCAAAGAGTATGAGCCAATATTTGG
GCTGATGCAGGAGAAAATTTACATCAGCAAGATTGTTGTTGAGTTCCTGCAAA
ACAATCCTGATGCTGTATATGAAGACCTGATCAATAAGATTGAGACCACTGTT
CCTCCTTCTACCATTAATGTGAACCGGTTCACAGAGGACTCCCTCTTACGCCA
CGCCCAGTTTGTAGTGAGCCAGGTAGAGAGTTACGACGAAGCCAAGGACGAT
GATGAGACCCCCATCTTCTTGTCTCCCTGTATGAGAGCCCTGATCCATTTGGCT
GGTGTCTCCCTGGGACAGAGGCGAGCAACAAGGCGCGTCATGGGTGCTACCA
AGGAGAAGGACAAAGCACCCACGAAAGCCACCACCACCAAGCTGGTCTATCA
GATCTTTGACACTTTCTTCTCAGAGCAGATTGAGAAGTATGATAAGGAGGACA
AGGAGAATGCCATGAAGCGCCGCCGCTGTGGTGTCTGTGAGGTCTGTCAGCA
GCCTGAGTGTGGGAAGTGCAAGGCGTGCAAAGATATGGTGAAGTTTGGTGGC
ACTGGACGGAGTAAGCAGGCTTGCCTCAAGAGGAGGTGTCCTAACTTGGCGG
TGAAGGAGGCAGACGACGATGAAGAGGCTGATGATGATGTGTCAGAGATGCC
ATCACCCAAAAAGCTGCATCAGGGGAAGAAGAAGAAGCAGAACAAGGACCG
CATCTCCTGGCTTGGGCAGCCTATGAAGATTGAAGAGAATAGAACTTACTATC
AGAAGGTGAGCATCGATGAGGAGATGCTAGAGGTGGGCGACTGCGTCTCGGT
CATTCCAGATGATTCCTCCAAACCACTCTATCTAGCCAGGGTCACAGCTCTGT
GGGAAGACAAAAATGGTCAGATGATGTTCCATGCGCACTGGTTCTGCGCTGG
GACAGACACAGTCCTGGGAGCCACCTCCGACCCCCTGGAACTGTTCCTGGTG
GGCGAGTGCGAAAACATGCAGCTTTCCTACATCCACAGCAAGGTCAAGGTCA
TCTACAAAGCCCCTTCTGAAAACTGGGCCATGGAGGGAGGCACAGACCCTGA
GACCACACTGCCTGGGGCTGAGGATGGCAAGACTTACTTCTTCCAGCTCTGGT
ACAACCAGGAGTACGCAAGGTTTGAATCCCCACCCAAGACCCAGCCGACCGA
GGACAACAAGCACAAGTTCTGCCTATCTTGTATCCGGCTGGCTGAGCTGAGAC
AAAAAGAAATGCCCAAGGTCCTGGAACAAATTGAGGAGGTGGATGGCCGGGT
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CTACTGCAGTTCCATCACCAAGAATGGTGTTGTCTACCGACTGGGTGACAGTG
TGTACCTTCCTCCCGAGGCCTTTACTTTCAACATCAAAGTGGCTAGCCCCGTG
AAACGCCCAAAGAAGGATCCTGTGAACGAGACCCTGTACCCTGAGCACTACC
GCAAGTATTCTGACTACATCAAGGGGAGCAACCTGGATGCTCCAGAGCCCTAT
CGCATCGGTCGGATAAAAGAGATCCACTGTGGCAAGAAGAAAGGCAAGGTCA
ACGAGGCAGACATCAAGCTGAGGCTCTACAAGTTCTACAGGCCTGAGAATAC
CCACAGGTCCTACAACGGATCCTATCACACTGACATCAACATGCTTTACTGGA
GCGACGAGGAAGCTGTGGTGAACTTCAGCGACGTGCAGGGCCGCTGTACCGT
GGAGTACGGGGAAGACCTACTTGAGAGCATCCAGGATTATTCACAAGGGGGC
CCTGACCGCTTCTACTTCCTCGAGGCCTACAATTCAAAGACCAAGAACTTTGA
AGACCCACCAAACCATGCCCGCAGCCCTGGGAACAAAGGGAAAGGGAAGGG
GAAAGGGAAGGGGAAGGGGAAGCATCAGGTGTCAGAGCCCAAAGAGCCTGA
GGCAGCCATCAAACTGCCCAAGCTCCGGACCCTGGATGTGTTTTCCGGCTGTG
GAGGGTTATCGGAAGGATTCCACCAAGCAGGCATCTCGGAAACGCTGTGGGC
CATCGAGATGTGGGACCCGGCAGCCCAGGCATTTCGGCTGAACAACCCCGGC
ACCACAGTGTTCACAGAGGACTGCAACGTGCTTCTTAAGCTGGTCATGGCTGG
GGAGGTGACCAACTCTCTGGGCCAAAGGCTGCCACAGAAGGGCGATGTGGA
GATGCTGTGTGGTGGGCCACCCTGCCAGGGCTTCAGTGGCATGAACCGCTTC
AACTCCCGCACTTACTCCAAGTTCAAAAACTCCCTAGTGGTCTCCTTCCTCAGC
TACTGTGACTACTACCGGCCTCGGTTCTTCCTTCTGGAGAACGTCAGGAACTT
CGTGTCCTACAGACGCTCCATGGTGCTGAAGCTCACACTGCGCTGCCTGGTCC
GCATGGGCTACCAGTGCACCTTTGGTGTGCTCCAGGCTGGACAGTATGGCGT
GGCCCAGACACGAAGGAGGGCCATCATCTTGGCTGCAGCCCCAGGAGAAAA
GCTGCCTCTGTTCCCAGAGCCTCTGCATGTGTTTGCGCCCCGTGCCTGCCAGC
TGAGCGTTGTGGTGGATGACAAGAAGTTTGTTAGCAACATAACGAGGCTGAG
CTCGGGGCCCTTCCGAACCATCACCGTGCGAGACACCATGTCTGACCTCCCC
GAGATCCAGAATGGAGCCTCGAATTCTGAGATCCCCTACAATGGAGAGCCAC
TGTCCTGGTTCCAGAGGCAGCTGCGAGGATCACACTACCAGCCCATCCTCAG
GGACCATATCTGCAAGGACATGAGCCCACTGGTGGCTGCCCGCATGCGGCAC
ATCCCACTGTTCCCAGGATCAGATTGGCGTGACCTGCCCAACATACAGGTGCG
GCTGGGAGATGGCGTCATAGCCCATAAGCTACAGTACACCTTTCATGATGTGA
AAAATGGCTACAGCAGCACCGGTGCCCTGCGTGGAGTCTGTTCCTGTGCAGA
AGGCAAGGCCTGCGACCCTGAGTCCAGGCAATTCAGCACCCTCATCCCCTGG
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TGCCTGCCGCACACTGGGAACCGGCACAACCACTGGGCTGGCCTCTACGGGC
GTCTGGAGTGGGATGGCTTCTTCAGCACCACTGTCACCAACCCTGAGCCCATG
GGCAAGCAGGGTCGGGTGCTCCACCCGGAGCAGCACCGGGTCGTGAGTGTT
CGGGAATGTGCCCGCTCCCAGGGCTTTCCAGATAGCTACCGGTTCTTCGGCAA
CATCCTGGACAGACACCGGCAGGTGGGTAATGCTGTGCCACCACCCCTGGCC
AAAGCCATTGGCCTGGAGATTAAGCTCTGCCTGCTGTCCAGTGCTCGGGAGA
GCGCATCAGCTGCAGTTAAAGCAAAAGAGGAGGCTGCTACCAAGGACTAGTG
CTCTCACCCAGAGCCCCACGTGCACTGATGTTTTTAACCCTTTGAGCCCCATC
ATTTGAAGTCTTGTGCTCAGTGTCTGTGGCCATGGCTGACACTAAGCTGTTTGT
ATGAGGTTTGTTTTGTGACCAAGCTGTGTAGTACTTTGTGCATTCTGAATTTTAA
GGTTTTTTTTTTTGTTTGGTTTGGTTTGGTTTGGTTTTTTTCTTATCCTGTATTCTA
TCAGATCCCCCGGGCCTAGGAGATCTCACCGGTGACTAGTCAGGGGGGATCT
GCATGGATCTTTGTGAAGGAACCTTACTTCTGTGGTGTGACATAATTGGACAA
ACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAATTTTTAAGTGTATA
ATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTCCAACCTATGGA
ACTGATGAATGGGAGCAGTGGTGGAATGCCAGATCCAGACATGATAAGATAC
ATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTAT
TTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAA
CAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGT
GTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATT
ATGATCTGC 
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